{"meta":{"query_hash":"4ceb0606b211","filters":{"venue":"HIV Clinical Trials"},"cohort_total":57,"direct_labels_cover":4,"predictions_cover":57,"exported":57,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4ceb0606b211","api":"https://metacan.xera.ac/api/v1/cohort?venue=HIV+Clinical+Trials"},"results":[{"id":"W118439278","doi":"10.1310/m0cv-r6bx-a9dp-jjv0","title":"Circulating Levels of IL-7 but not IL-15, IGF-1, and TGF-β Are Elevated During Primary HIV-1 Infection","year":2004,"lang":"en","type":"letter","venue":"HIV Clinical Trials","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Medicine; Transforming growth factor; Human immunodeficiency virus (HIV); Immunology; Virology; Internal medicine","score_opus":0.14433336507600897,"score_gpt":0.36135788290214543,"score_spread":0.21702451782613646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W118439278","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1530583,0.022210002,0.0015692922,0.7493504,0.036746193,0.00018591419,0.0004745244,0.00035695368,0.036048364],"genre_scores_gemma":[0.54840195,0.008005294,0.0011877283,0.35286844,0.061338592,0.0002986229,0.00022564684,0.0000674648,0.02760627],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992531,0.00034621448,0.00007362887,0.000043207714,0.00015053386,0.00013323543],"domain_scores_gemma":[0.9974905,0.0018348466,0.00012408914,0.000092000184,0.0002606422,0.0001978109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095660234,0.00042735983,0.00123754,0.00024031317,0.000678972,0.0011033256,0.0006259391,0.0052718963,0.0018239608],"category_scores_gemma":[0.0055312444,0.00021087803,0.0003108309,0.0002338779,0.00078366016,0.0006477652,0.00016346828,0.0039122473,0.0009693275],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0136267245,0.0007017323,0.03645834,0.0007979913,0.00024110178,0.067655765,0.0005870141,0.0005751154,0.019041272,0.0038275097,0.6298455,0.22664194],"study_design_scores_gemma":[0.005333251,0.0074126394,0.10947817,0.0009202038,0.00056791137,0.074284665,0.0013498388,0.0035748568,0.022650639,0.012605369,0.7616288,0.00019354929],"about_ca_topic_score_codex":0.001093043,"about_ca_topic_score_gemma":0.0019861753,"teacher_disagreement_score":0.0052718963,"about_ca_system_score_codex":0.0013792483,"about_ca_system_score_gemma":0.00059148873,"threshold_uncertainty_score":0.010007203},"labels":[],"label_agreement":null},{"id":"W1963635957","doi":"10.1310/hct0902-73","title":"Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients","year":2008,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Tolerability; Enfuvirtide; Dosing; Regimen; Adverse effect; Pharmacokinetics; Internal medicine; Pharmacology; Immunology","score_opus":0.1454580302820737,"score_gpt":0.40894059936397603,"score_spread":0.2634825690819023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963635957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977349,0.0013390222,0.000100160345,0.000099884375,0.000036779347,0.0001261001,0.00010026499,0.000023670202,0.00043920724],"genre_scores_gemma":[0.9985228,0.00034020827,0.00027705147,0.0001440505,0.00005394625,0.00016207775,0.00011552617,0.000004476122,0.00037992015],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994917,0.0002545914,0.000036402256,0.00010180214,0.00005525304,0.00006013067],"domain_scores_gemma":[0.9991504,0.00021921005,0.00030483218,0.000056452365,0.00003504786,0.00023408898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010323628,0.0006911956,0.0014550928,0.00021480538,0.00026545746,0.0005268561,0.00040992367,0.000958864,0.0027001256],"category_scores_gemma":[0.0017829788,0.00041150668,0.00082150364,0.00016124602,0.0004155439,0.0007954543,0.00022402387,0.0012272549,0.0003991246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85289085,0.015961913,0.006727071,0.0003905777,0.0005276569,0.000096369615,0.00014714665,0.0010397497,0.017286895,0.00007872468,0.0006359761,0.10421703],"study_design_scores_gemma":[0.25919795,0.6858124,0.046271257,0.00006519536,0.0005975053,0.00025502167,0.000092420974,0.0024069145,0.0039780843,0.00019771511,0.0010716856,0.000053861084],"about_ca_topic_score_codex":0.0004039728,"about_ca_topic_score_gemma":0.0007126691,"teacher_disagreement_score":0.0027001256,"about_ca_system_score_codex":0.00045382723,"about_ca_system_score_gemma":0.00042033935,"threshold_uncertainty_score":0.009032786},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W1965528887","doi":"10.1310/q2l2-qvrk-4e01-c8f8","title":"Progression to AIDS or Death as Endpoints in HIV Clinical Trials","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Styrelsen för Internationellt Utvecklingssamarbete","keywords":"Medicine; Regimen; Internal medicine; Clinical endpoint; Clinical trial; Cohort; Antiretroviral therapy; Human immunodeficiency virus (HIV); Protease inhibitor (pharmacology); Viral load; Oncology; Immunology","score_opus":0.5056012280870779,"score_gpt":0.6012395459815103,"score_spread":0.09563831789443245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965528887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52028275,0.36056313,0.031080116,0.007933839,0.00270936,0.048165802,0.00896609,0.0005291179,0.019769808],"genre_scores_gemma":[0.8664512,0.024252422,0.024967926,0.002661179,0.0013582999,0.07352278,0.0034779075,0.0001177259,0.003190552],"study_design_codex":"randomized_trial","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7219256,0.25775686,0.010820062,0.0031349547,0.0054874155,0.00087512995],"domain_scores_gemma":[0.7931687,0.16024552,0.033462632,0.0045630033,0.0044262726,0.0041338373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.1335914,0.0020319866,0.0050784633,0.0027703831,0.0008143019,0.0031948844,0.0012560406,0.0032127392,0.0032117835],"category_scores_gemma":[0.14649542,0.00063868205,0.003830205,0.0033122934,0.0021988258,0.002454446,0.0019919,0.00302048,0.00042925327],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68854165,0.0021897524,0.07400732,0.032960217,0.030927556,0.0004010702,0.0006157134,0.0083286995,0.0011844905,0.007328627,0.007229313,0.14628561],"study_design_scores_gemma":[0.43304625,0.23325677,0.15379485,0.014013753,0.025523013,0.0021462583,0.00075635413,0.04077253,0.004406441,0.02251601,0.06928201,0.00048572948],"about_ca_topic_score_codex":0.00024159208,"about_ca_topic_score_gemma":0.0004337545,"teacher_disagreement_score":0.1335914,"about_ca_system_score_codex":0.0014600139,"about_ca_system_score_gemma":0.002682104,"threshold_uncertainty_score":0.7065073},"labels":[],"label_agreement":null},{"id":"W1965948300","doi":"10.1310/hct1104-186","title":"Randomized, Comparative, Double-Blind, Double-Dummy, Multicenter Trial of Miconazole Buccal Tablet and Clotrimazole Troches for the Treatment of Oropharyngeal Candidiasis: Study of Miconazole Lauriad<sup>®</sup>Efficacy and Safety (SMiLES)","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS oral health manifestations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Miconazole; Clotrimazole; Buccal administration; Clinical trial; Randomized controlled trial; Adverse effect; Internal medicine; Pharmacology; Antifungal; Dermatology","score_opus":0.2931300087889962,"score_gpt":0.5013441931525906,"score_spread":0.2082141843635944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965948300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055207,0.0023592087,0.0004991947,0.00043141222,0.0003966321,0.0039279517,0.0005961951,0.00011278353,0.0011246576],"genre_scores_gemma":[0.9863239,0.0015652002,0.0018752521,0.0010156323,0.0005757314,0.0058127097,0.00089459086,0.00003530563,0.0019016385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841297,0.00095752924,0.00010640786,0.00025035546,0.000097212076,0.0001754811],"domain_scores_gemma":[0.9971777,0.0009987383,0.0006965014,0.0002611241,0.00019184966,0.00067408447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033365265,0.0021590793,0.0039976723,0.0005343933,0.0005839388,0.0013003158,0.0014261289,0.0027999775,0.006435498],"category_scores_gemma":[0.003667836,0.0011057288,0.0018553319,0.00050488405,0.0021322242,0.0014407178,0.00050195045,0.0032643,0.0012443246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9876835,0.006018455,0.00021075217,0.00019346827,0.00028343746,0.00001436615,0.00002907261,0.0000934895,0.0013211275,0.00004289693,0.00019714115,0.003912308],"study_design_scores_gemma":[0.94501317,0.05371943,0.00055100385,0.000010499442,0.0001308236,0.000013395658,0.000008947608,0.00018558458,0.00019712486,0.000036058584,0.00012766213,0.0000062687322],"about_ca_topic_score_codex":0.00083330215,"about_ca_topic_score_gemma":0.0014172177,"teacher_disagreement_score":0.006435498,"about_ca_system_score_codex":0.00079253234,"about_ca_system_score_gemma":0.0017453632,"threshold_uncertainty_score":0.02152884},"labels":[],"label_agreement":null},{"id":"W1970014945","doi":"10.1310/xp75-7vj5-hml2-yf1w","title":"Update on HIV Lipodystrophy","year":2004,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Lipodystrophy; Medicine; Antiretroviral therapy; Adverse effect; Human immunodeficiency virus (HIV); Pathogenesis; Intensive care medicine; Immunology; Internal medicine; Viral load","score_opus":0.4353347746231593,"score_gpt":0.579937942091974,"score_spread":0.14460316746881474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970014945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000074425814,0.99692446,0.000066248926,0.00042138403,0.0006060727,0.000014942694,0.000048864826,0.000010092939,0.0018334347],"genre_scores_gemma":[0.00030768962,0.99733067,0.00022593126,0.00048079604,0.00037169995,0.000016562106,0.000081696904,0.0000014989259,0.0011834053],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951816,0.000108182445,0.00010899362,0.000043411015,0.00019381705,0.000027389586],"domain_scores_gemma":[0.9988997,0.00057320745,0.00017920617,0.000024336281,0.00025439673,0.0000691806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094934285,0.0010413576,0.0023337621,0.0048924256,0.00034581518,0.0014148725,0.0013261422,0.0015723222,0.011345432],"category_scores_gemma":[0.0016289683,0.0004629984,0.0007634418,0.004890165,0.0003546941,0.0019796225,0.00069008034,0.0017514052,0.004815682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009580455,0.00008322127,0.00018633492,0.03865849,0.0001771492,0.00042836802,0.00009325061,0.0002412457,0.0005533925,0.0014759218,0.10742245,0.8505844],"study_design_scores_gemma":[0.000028669656,0.00006881055,0.0008960828,0.013533776,0.0002086318,0.0015755189,0.00006480528,0.000040613562,0.00009145061,0.00052714674,0.98295206,0.000012451934],"about_ca_topic_score_codex":0.0033255306,"about_ca_topic_score_gemma":0.00852346,"teacher_disagreement_score":0.011345432,"about_ca_system_score_codex":0.0008776998,"about_ca_system_score_gemma":0.0020819788,"threshold_uncertainty_score":0.03795427},"labels":[],"label_agreement":null},{"id":"W1970660282","doi":"10.1310/9m23-qn0x-w6n8-80jd","title":"Long-Term Follow-up of a Cohort of HIV-Infected Patients Who Discontinued Maintenance Therapy for Cytomegalovirus Retinitis","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Lunenfeld-Tanenbaum Research Institute; Sunnybrook Hospital; University of Toronto; University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Cytomegalovirus retinitis; Medicine; Discontinuation; Retinitis; Maintenance therapy; Cohort; Internal medicine; Cytomegalovirus; Prospective cohort study; Immunology; Human cytomegalovirus; Viral disease; Human immunodeficiency virus (HIV); Herpesviridae; Chemotherapy; Virus","score_opus":0.11841626984675059,"score_gpt":0.42888575966109255,"score_spread":0.31046948981434197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970660282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995858,0.00011685347,0.00004684838,0.000024708985,0.000005583163,0.0000063024163,0.00009936681,0.0000015733983,0.000112942565],"genre_scores_gemma":[0.99942917,0.00006443254,0.00004687822,0.000034611123,0.000012950907,0.0000094310735,0.00027383975,0.0000013947165,0.00012723198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996238,0.00007709567,0.000028471777,0.000090860136,0.00007000728,0.000109783505],"domain_scores_gemma":[0.99835676,0.0002880172,0.00055874535,0.00015664082,0.00021325648,0.00042657746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860276,0.0003500114,0.00055782666,0.0006193904,0.00095613406,0.0009508568,0.0003064002,0.00056171935,0.0010247012],"category_scores_gemma":[0.0027432588,0.00030989057,0.0005486118,0.00046282655,0.00028357012,0.0007449385,0.00037335543,0.0010698758,0.00030296994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024058326,0.00009923587,0.9974921,0.0000037268483,0.00004191561,0.00026031444,0.00008211477,0.000030850093,0.00034955633,0.000007388447,0.00006092477,0.0013313884],"study_design_scores_gemma":[0.0000392584,0.0008953232,0.99654764,0.000012422717,0.00007935166,0.0013895434,0.0002342779,0.00031196192,0.00015998441,0.000025531266,0.0002952844,0.0000094730385],"about_ca_topic_score_codex":0.003203907,"about_ca_topic_score_gemma":0.0019119477,"teacher_disagreement_score":0.003203907,"about_ca_system_score_codex":0.00031136387,"about_ca_system_score_gemma":0.0003520838,"threshold_uncertainty_score":0.006370485},"labels":[],"label_agreement":null},{"id":"W1971304024","doi":"10.1310/hct0801-36","title":"Virologic and Immunologic Impact and Durability of Enfuvirtide-Based Antiretroviral Therapy in HIV-Infected Treatment-Experienced Patients in a Clinical Setting","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Maple Leaf Medical Clinic","funders":"Canadian Institutes of Health Research","keywords":"Enfuvirtide; Medicine; Interquartile range; Viral load; Discontinuation; Internal medicine; Regimen; Hazard ratio; Retrospective cohort study; Adverse effect; Salvage therapy; Gastroenterology; Human immunodeficiency virus (HIV); Confidence interval; Immunology; Chemotherapy","score_opus":0.13038906756558047,"score_gpt":0.4729908189783467,"score_spread":0.3426017514127663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971304024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99895453,0.00068831776,0.000038104452,0.000026009724,0.0000027062692,0.000009829489,0.000070155096,0.000001626867,0.00020865635],"genre_scores_gemma":[0.9996346,0.000101208934,0.000066518405,0.000030897703,0.000012265081,0.0000056229032,0.00010845756,7.198551e-7,0.000039722305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988512,0.00061375636,0.000121239966,0.00012117605,0.00019613146,0.00009660407],"domain_scores_gemma":[0.9958912,0.0011362027,0.0022254076,0.00010572531,0.00024988034,0.00039156343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018695947,0.00022335694,0.00043122604,0.00019024726,0.00030089935,0.00072277134,0.00020961091,0.00034174728,0.0010024308],"category_scores_gemma":[0.0054817176,0.00015710245,0.0002823117,0.00028443793,0.00024348902,0.00036627936,0.00022117185,0.00039581285,0.00014602888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003828101,0.00021850617,0.98757184,0.000055671717,0.00014896039,0.00014514495,0.000042326687,0.00012719889,0.0010062688,0.00001669849,0.000095539785,0.0067436993],"study_design_scores_gemma":[0.00025551632,0.0034246414,0.9934918,0.000024582343,0.00010882346,0.0011494141,0.000100893376,0.0005975293,0.0004915306,0.00003198836,0.00031407803,0.000009077555],"about_ca_topic_score_codex":0.00039675878,"about_ca_topic_score_gemma":0.00061982125,"teacher_disagreement_score":0.0018695947,"about_ca_system_score_codex":0.00025518273,"about_ca_system_score_gemma":0.00032144116,"threshold_uncertainty_score":0.009887457},"labels":[],"label_agreement":null},{"id":"W1981322336","doi":"10.1310/b45n-4xhb-53lu-jax9","title":"Selected Topics from the 38th Annual Meeting of the Infectious Diseases Society of America, September 7-10, 2000, New Orleans, Louisiana and Selected Topics from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Ontario, Canada","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gerontology; Antimicrobial; Library science; Microbiology","score_opus":0.03259492114428208,"score_gpt":0.3132397287706411,"score_spread":0.280644807626359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981322336","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050080386,0.12981607,0.0032125472,0.03156911,0.06805027,0.0013946192,0.0076944665,0.00092374295,0.75233114],"genre_scores_gemma":[0.0041295826,0.06605519,0.001099827,0.0043790448,0.01567835,0.000333269,0.002993867,0.00013325122,0.9051977],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99950063,0.00006183926,0.0000374659,0.00006753046,0.0002360878,0.000096523],"domain_scores_gemma":[0.9983834,0.0001429608,0.00013544656,0.000024314751,0.00071744283,0.0005964659],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007992857,0.0026412497,0.0017746371,0.0017015622,0.00086501654,0.0028062754,0.00076528604,0.0021536322,0.31008],"category_scores_gemma":[0.0014344833,0.00042936805,0.0007678439,0.0013676096,0.0006013981,0.0011847842,0.0010801249,0.0022356214,0.21729839],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016067582,0.00007757765,0.00062438473,0.00046917613,0.000020347843,0.00009659208,0.00002552605,0.00007437907,0.0007907176,0.00021497007,0.9289384,0.068507224],"study_design_scores_gemma":[0.00006861281,0.0001533527,0.005187793,0.00056550454,0.000030275398,0.00013248567,0.000074223026,0.00006805485,0.00023892517,0.0002202495,0.99323773,0.00002277092],"about_ca_topic_score_codex":0.0047095455,"about_ca_topic_score_gemma":0.019378072,"teacher_disagreement_score":0.99529046,"about_ca_system_score_codex":0.0013481067,"about_ca_system_score_gemma":0.0014056381,"threshold_uncertainty_score":0.98408717},"labels":[],"label_agreement":null},{"id":"W1982283413","doi":"10.1310/hct1306-301","title":"Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; AIDS Vancouver; University of British Columbia; Centre Hospitalier de l’Université de Montréal; Centre hospitalier universitaire de Québec; Ottawa Hospital; University of Ottawa; Royal Victoria Hospital; McGill University Health Centre; Université de Montréal; Royal Victoria Regional Health Centre","funders":"National Institute on Drug Abuse; Ontario HIV Treatment Network","keywords":"Medicine; Crossover study; Valproic Acid; Clinical study design; Clinical trial; Human immunodeficiency virus (HIV); Randomized controlled trial; Crossover; Research design; Oncology; Pharmacology; Internal medicine; Immunology; Epilepsy; Pathology","score_opus":0.24160368954978242,"score_gpt":0.5034676164749569,"score_spread":0.26186392692517446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982283413","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4220981,0.0014895819,0.011461932,0.00087037554,0.0036762175,0.55508655,0.0016472207,0.00032594727,0.00334401],"genre_scores_gemma":[0.33477157,0.00069887005,0.028856589,0.0017293192,0.0019191374,0.6283399,0.0006072045,0.0000497971,0.0030276664],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9797539,0.012656727,0.0016664655,0.0025764832,0.0014882429,0.0018581656],"domain_scores_gemma":[0.98575205,0.0054680207,0.0027292327,0.0024562401,0.0017226094,0.0018718821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02359429,0.004058609,0.0065474263,0.001487336,0.0015464703,0.0017179291,0.0019344396,0.0053199613,0.014043299],"category_scores_gemma":[0.017508663,0.0016578346,0.0027106563,0.0012578951,0.003259102,0.0019610017,0.0013465862,0.0035053052,0.001964823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93975633,0.04469726,0.0007695472,0.0006463493,0.00055279856,0.00005704542,0.00013783162,0.00047719083,0.0022333548,0.00050757575,0.0004948718,0.009669896],"study_design_scores_gemma":[0.6868548,0.30788124,0.0015142028,0.000052469768,0.0003481519,0.000016517904,0.000033489312,0.00047433257,0.0006791352,0.00046845293,0.0016466907,0.000030644187],"about_ca_topic_score_codex":0.000582042,"about_ca_topic_score_gemma":0.0005447621,"teacher_disagreement_score":0.02359429,"about_ca_system_score_codex":0.0013421567,"about_ca_system_score_gemma":0.0052063097,"threshold_uncertainty_score":0.12478},"labels":[],"label_agreement":null},{"id":"W1985542358","doi":"10.1179/1528433614z.0000000005","title":"<i>Tripterygium wilfordii</i>Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety","year":2015,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Natural Compounds in Disease Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"University of California, San Francisco","keywords":"Medicine; Tripterygium wilfordii; Discontinuation; Tripterygium; Cart; Immune system; Triptolide; Internal medicine; Combination therapy; T cell; Pharmacology; Immunology; Apoptosis","score_opus":0.19265507057799972,"score_gpt":0.43823313118125,"score_spread":0.2455780606032503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985542358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99858177,0.0008330668,0.00006683514,0.000038714577,0.00001181789,0.00021553611,0.00005448229,0.000005288434,0.00019266344],"genre_scores_gemma":[0.99845064,0.000594795,0.00022891579,0.0001435727,0.000045881763,0.0001625566,0.00011656926,0.000001857889,0.00025516027],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99987113,0.00005258428,0.000009577642,0.000020045249,0.000015141773,0.000031547814],"domain_scores_gemma":[0.99977535,0.000055625173,0.000055679946,0.000015691028,0.000019286163,0.0000783885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043121903,0.00030805718,0.00070259813,0.00017851796,0.0002803462,0.00025945963,0.00020601408,0.00037240528,0.0017236475],"category_scores_gemma":[0.00039913738,0.00013781381,0.0004662461,0.00014148108,0.00022088124,0.00028456567,0.00017338154,0.00047220718,0.00018366404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4086229,0.09543078,0.09099961,0.0025745418,0.0017287136,0.0023239923,0.00097236806,0.0007423868,0.12195706,0.00017058196,0.002122543,0.27235445],"study_design_scores_gemma":[0.04610148,0.8038392,0.13737804,0.00012015114,0.00093455956,0.001108713,0.0003180819,0.0008173801,0.0062907375,0.0000735259,0.0029874449,0.000030684554],"about_ca_topic_score_codex":0.00051203213,"about_ca_topic_score_gemma":0.00079090684,"teacher_disagreement_score":0.0017236475,"about_ca_system_score_codex":0.00022247809,"about_ca_system_score_gemma":0.00034450815,"threshold_uncertainty_score":0.0057661533},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W1987974009","doi":"10.1310/hct0804-213","title":"Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Darunavir; Ritonavir; Tolerability; Internal medicine; Regimen; Gastroenterology; Adverse effect; Hepatitis B; Hepatitis C; Alanine transaminase; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.09964593074584223,"score_gpt":0.4511300174849633,"score_spread":0.35148408673912107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987974009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909779,0.007418789,0.00028832562,0.00019658988,0.000023061399,0.00030896562,0.00015972678,0.000016936467,0.0006096733],"genre_scores_gemma":[0.9971789,0.0013092643,0.00035812758,0.00024319312,0.00005353745,0.00032870687,0.00035039498,0.000008016618,0.00017000995],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9974369,0.0018922833,0.00020768787,0.00017091206,0.00015567495,0.00013655737],"domain_scores_gemma":[0.9974107,0.0010566877,0.000901623,0.00017698172,0.00014212231,0.0003119702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047629215,0.00063620124,0.0015669641,0.000298823,0.00023863134,0.00085746666,0.00050090346,0.0006456831,0.0016300598],"category_scores_gemma":[0.004932616,0.00030667023,0.0025401274,0.0004079961,0.00063092285,0.00080049725,0.00043304058,0.0012021202,0.00024086186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76312006,0.0035551125,0.0737532,0.0019732541,0.0077307574,0.00029084578,0.00042708247,0.0017501964,0.010792812,0.00020206528,0.0016171957,0.13478744],"study_design_scores_gemma":[0.4452388,0.3792976,0.15248574,0.000356112,0.008616622,0.001364468,0.00018949615,0.0020559542,0.0052530933,0.00058977207,0.004478663,0.00007368113],"about_ca_topic_score_codex":0.00028387958,"about_ca_topic_score_gemma":0.00068480085,"teacher_disagreement_score":0.0047629215,"about_ca_system_score_codex":0.0005135816,"about_ca_system_score_gemma":0.00067569374,"threshold_uncertainty_score":0.025189042},"labels":[],"label_agreement":null},{"id":"W1988113084","doi":"10.1310/f45l-fdkk-y48n-n2bt","title":"Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure","year":2001,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Nelfinavir; Medicine; Viral load; Quartile; Protease inhibitor (pharmacology); Internal medicine; Amprenavir; Indinavir; Area under the curve; Gastroenterology; Immunology; Pharmacology; Confidence interval; Virus; Protease; Antiretroviral therapy","score_opus":0.336951842305224,"score_gpt":0.4781353444316747,"score_spread":0.1411835021264507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988113084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981488,0.0010143043,0.00016123972,0.000025754056,0.000022231641,0.000083168736,0.00014010954,0.000005747702,0.0003986678],"genre_scores_gemma":[0.99864453,0.00019321838,0.00022585531,0.00006963648,0.000054928867,0.00018453825,0.00046777472,0.0000025244806,0.00015710354],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99794203,0.0010288871,0.00024763876,0.00029452064,0.000218273,0.00026855772],"domain_scores_gemma":[0.9971413,0.0014217122,0.0005612683,0.0002900193,0.00018359901,0.00040199564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023258817,0.00037234667,0.0012003816,0.00032041952,0.00018944083,0.0006334043,0.0003025211,0.00067127845,0.0014109362],"category_scores_gemma":[0.0036993749,0.00026652287,0.00088217086,0.000337997,0.00043387173,0.00060386164,0.000275743,0.0010090681,0.00022292313],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8507496,0.009051963,0.038297962,0.0004371828,0.0026181485,0.00018008924,0.00019140585,0.0019478808,0.0423766,0.00018379852,0.00050031225,0.053465087],"study_design_scores_gemma":[0.08001123,0.7420616,0.14962572,0.00006241125,0.0025782764,0.0004510477,0.00010642056,0.0021652458,0.020622086,0.00038361983,0.0018911896,0.000041117855],"about_ca_topic_score_codex":0.00012421967,"about_ca_topic_score_gemma":0.00016006936,"teacher_disagreement_score":0.0023258817,"about_ca_system_score_codex":0.00030643438,"about_ca_system_score_gemma":0.00032241223,"threshold_uncertainty_score":0.012300551},"labels":[],"label_agreement":null},{"id":"W1988473048","doi":"10.1310/feed-6t8u-0bug-6hqh","title":"Randomized Trials Stopped Early for Harm in HIV/AIDS: A Systematic Survey","year":2006,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia; AIDS Vancouver; University of Ottawa","funders":"International AIDS Society","keywords":"Medicine; Data monitoring committee; Interim; Harm; Randomized controlled trial; Adverse effect; Psychological intervention; Clinical trial; Population; Family medicine; Environmental health; Internal medicine; Psychiatry","score_opus":0.9477098910306675,"score_gpt":0.7483044210610479,"score_spread":0.1994054699696196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988473048","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04277086,0.91269183,0.009519934,0.0071580047,0.00086675066,0.01724971,0.0072897403,0.00022367634,0.0022295543],"genre_scores_gemma":[0.3821701,0.48362973,0.04868992,0.015591522,0.0009051153,0.06048175,0.007302799,0.00026684251,0.000962267],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.47140482,0.2259313,0.24898149,0.01229751,0.039429378,0.001955597],"domain_scores_gemma":[0.15346098,0.60910475,0.18168257,0.015966862,0.036933746,0.0028511635],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.3155687,0.001582632,0.010422955,0.0161679,0.0014336024,0.007089071,0.0028942395,0.0042287717,0.003507118],"category_scores_gemma":[0.63024414,0.0022308996,0.011512571,0.019885596,0.0033190458,0.011415536,0.0040169135,0.0039123883,0.00064400473],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045117442,0.00018702386,0.055073064,0.7426156,0.040081087,0.00021890219,0.00282602,0.000547873,0.00040461394,0.0030176064,0.008205337,0.14231111],"study_design_scores_gemma":[0.0042398046,0.0014882021,0.05583158,0.84693265,0.048953675,0.0008612068,0.002165788,0.0010000085,0.0008269304,0.0054234834,0.032056555,0.00022009423],"about_ca_topic_score_codex":0.0021236967,"about_ca_topic_score_gemma":0.0040469146,"teacher_disagreement_score":0.98957705,"about_ca_system_score_codex":0.006116856,"about_ca_system_score_gemma":0.014214526,"threshold_uncertainty_score":0.8440257},"labels":[],"label_agreement":null},{"id":"W1990715538","doi":"10.1310/hct0901-43","title":"Systematic Review and Meta–Analysis of the Diagnostic Accuracy of Fibrosis Marker Panels in Patients with HIV/Hepatitis C Coinfection","year":2008,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Liver Foundation","keywords":"Medicine; Cirrhosis; Receiver operating characteristic; Fibrosis; Internal medicine; Coinfection; Hepatitis C; Liver biopsy; Hepatitis C virus; Gastroenterology; Meta-analysis; Odds ratio; Biopsy; Human immunodeficiency virus (HIV); Pathology; Immunology; Virus","score_opus":0.28699899790588745,"score_gpt":0.49542791165484074,"score_spread":0.20842891374895328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990715538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046678386,0.99339783,0.00045444898,0.00024768844,0.00013041847,0.0002545988,0.0006002552,0.000021178428,0.00022581105],"genre_scores_gemma":[0.19683963,0.795909,0.0030574268,0.0010691178,0.00029132742,0.0012989207,0.0012071214,0.000033522036,0.0002939557],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9842152,0.008705362,0.0040385784,0.0013225501,0.0013835576,0.00033476076],"domain_scores_gemma":[0.9586964,0.032778624,0.0052561085,0.0009613477,0.002018285,0.0002892236],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.01739136,0.002661172,0.017441904,0.0075597125,0.000717205,0.003307529,0.0019742232,0.002308948,0.0027867653],"category_scores_gemma":[0.05497394,0.0014213895,0.030181548,0.0076456717,0.000896352,0.0016650781,0.0014164593,0.0017057906,0.00025219755],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013219925,0.000018230487,0.005385456,0.40116563,0.5787232,0.00016811192,0.00008290837,0.0006511523,0.00019299069,0.00014753624,0.00088716595,0.011255516],"study_design_scores_gemma":[0.0003908304,0.00014352721,0.004552956,0.035809513,0.95679444,0.00013238168,0.000033305943,0.00022001388,0.00011353407,0.00021308559,0.0015771636,0.000019311661],"about_ca_topic_score_codex":0.008893125,"about_ca_topic_score_gemma":0.01739762,"teacher_disagreement_score":0.9825581,"about_ca_system_score_codex":0.0032044975,"about_ca_system_score_gemma":0.004470661,"threshold_uncertainty_score":0.09197539},"labels":[],"label_agreement":null},{"id":"W1991408322","doi":"10.1310/hct0806-400","title":"Effectiveness and Tolerability of Oral Administration of Low-Dose Salmon Oil to HIV Patients with HAART-Associated Dyslipidemia","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Abbott (Canada); Université Laval; Centre hospitalier de l'Université Laval; Maple Leaf Medical Clinic","funders":"Abbott Canada; Abbott Laboratories","keywords":"Medicine; Dyslipidemia; Tolerability; Fish oil; Adverse effect; Concomitant; Internal medicine; Triglyceride; Gastroenterology; Cholesterol; Fish <Actinopterygii>; Fishery; Disease","score_opus":0.09556612374720039,"score_gpt":0.4636352470363737,"score_spread":0.3680691232891733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991408322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973863,0.002057161,0.00009707276,0.00008906751,0.00002752762,0.00009720802,0.000049227965,0.000010834408,0.00018557493],"genre_scores_gemma":[0.9985051,0.0006901284,0.0003380517,0.00011131959,0.000060142796,0.00008545937,0.00008283314,0.0000024449064,0.00012449274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99951947,0.00030020816,0.00004747392,0.000049716196,0.000043262287,0.000039962146],"domain_scores_gemma":[0.9989135,0.00033258618,0.00039408033,0.00005376444,0.000052782598,0.0002533676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091368175,0.0004623576,0.0013328829,0.0001931093,0.00022298498,0.00044419,0.00033231967,0.0006369924,0.0016843219],"category_scores_gemma":[0.0018777371,0.00023618578,0.0006658613,0.00017189216,0.00047503083,0.00048229247,0.00019344784,0.0009970935,0.00015987213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81840706,0.018063273,0.018553188,0.00092510105,0.0013495791,0.00014165179,0.00013090721,0.0006081492,0.018469712,0.00006228428,0.0004302745,0.12285882],"study_design_scores_gemma":[0.24110024,0.69405526,0.055817544,0.00014931535,0.0012536132,0.0002729703,0.00014140722,0.0015440843,0.0045881704,0.00009403721,0.00094599574,0.00003741737],"about_ca_topic_score_codex":0.00039765204,"about_ca_topic_score_gemma":0.00094276597,"teacher_disagreement_score":0.0016843219,"about_ca_system_score_codex":0.00038762888,"about_ca_system_score_gemma":0.0005089986,"threshold_uncertainty_score":0.0056345463},"labels":[],"label_agreement":null},{"id":"W1992656981","doi":"10.1310/hct1006-413","title":"A Systematic Review of the Quality of Trials Evaluating Biomedical HIV Prevention Interventions Shows That Many Lack Power","year":2009,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Public Health Ontario; Hospital for Sick Children; Institute for Clinical Evaluative Sciences; McGill University; Mount Sinai Hospital; SickKids Foundation; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Medicine; Psychological intervention; Randomized controlled trial; Clinical trial; Systematic review; Human immunodeficiency virus (HIV); Intensive care medicine; MEDLINE; Family medicine; Internal medicine; Psychiatry","score_opus":0.9678022509413752,"score_gpt":0.8037718717577813,"score_spread":0.16403037918359387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992656981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00331761,0.985538,0.003387507,0.0046383208,0.00065861206,0.0009085462,0.00047505865,0.000037719816,0.0010386121],"genre_scores_gemma":[0.17989957,0.7772406,0.022097226,0.011682169,0.001272093,0.006343646,0.00082008325,0.00010621318,0.0005383667],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.59598786,0.2412351,0.10558751,0.011867493,0.04386975,0.0014522861],"domain_scores_gemma":[0.1304613,0.7728795,0.06379703,0.00955497,0.022152279,0.0011549297],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.28621405,0.0024138074,0.014585772,0.0070184455,0.0018805312,0.0088268025,0.0036381586,0.0049361885,0.004502798],"category_scores_gemma":[0.68542415,0.0024669608,0.009510606,0.012098567,0.005863823,0.0062399637,0.0031808654,0.0032801614,0.00064564554],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013441297,0.00005235891,0.008274044,0.7882284,0.049715556,0.00017920592,0.0008865188,0.00070435076,0.0003987741,0.002785193,0.0061798957,0.14125165],"study_design_scores_gemma":[0.0025650533,0.000968917,0.027895395,0.7657091,0.14668027,0.00093129993,0.0011839276,0.0008931208,0.0011974368,0.011804417,0.039971367,0.00019972988],"about_ca_topic_score_codex":0.0055615557,"about_ca_topic_score_gemma":0.012155566,"teacher_disagreement_score":0.71378595,"about_ca_system_score_codex":0.008156966,"about_ca_system_score_gemma":0.018983621,"threshold_uncertainty_score":0.8802252},"labels":[],"label_agreement":null},{"id":"W1996104688","doi":"10.1310/hct0805-259","title":"Randomized Controlled Trial of Once-Daily Tenofovir, Lamivudine, and Lopinavir/Ritonavir Versus Remaining on the Same Regimen in Virologically Suppressed HIV-Infected Patients on Their First PI-Containing HAART Regimen","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; McGill University; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; GDI Integrated Facility Services (Canada); St. Michael's Hospital; Western University; McMaster University Medical Centre; University of British Columbia; Abbott (Canada); University of Toronto","funders":"Abbott Canada; Gilead Sciences","keywords":"Medicine; Regimen; Lopinavir; Lamivudine; Ritonavir; Adverse effect; Discontinuation; Randomized controlled trial; Internal medicine; Lopinavir/ritonavir; Clinical endpoint; Viral load; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Virus; Antiretroviral therapy; Hepatitis B virus","score_opus":0.11908434106831939,"score_gpt":0.38938264742990997,"score_spread":0.2702983063615906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996104688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98293316,0.0035517577,0.0008668779,0.0010472436,0.001943174,0.0067556966,0.00096091314,0.00016683586,0.0017742969],"genre_scores_gemma":[0.98128915,0.0021344621,0.002594012,0.0018569924,0.0012179145,0.006647749,0.0008234422,0.000028504131,0.0034078774],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9982083,0.0011351065,0.00011522366,0.0002703353,0.00011251447,0.00015847635],"domain_scores_gemma":[0.99698025,0.0011708301,0.00059665594,0.00025535858,0.00019882096,0.00079807435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026941807,0.0021780492,0.004938562,0.0005942958,0.000745583,0.0019203064,0.001493465,0.003145514,0.008339358],"category_scores_gemma":[0.003835931,0.0011340037,0.0024486084,0.00054721266,0.001994183,0.0013384899,0.000519264,0.004568941,0.0011634562],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9919355,0.0041706176,0.000172895,0.00023229336,0.0004072585,0.000013734834,0.000019532512,0.000083578016,0.00046171242,0.000035804947,0.00015856448,0.0023084807],"study_design_scores_gemma":[0.97604895,0.023017008,0.00032450794,0.000012524833,0.0001760994,0.0000075527387,0.000008023655,0.0001966726,0.00007033904,0.000037334343,0.00009586565,0.000005052533],"about_ca_topic_score_codex":0.0015639076,"about_ca_topic_score_gemma":0.0031246585,"teacher_disagreement_score":0.008339358,"about_ca_system_score_codex":0.00085184723,"about_ca_system_score_gemma":0.0018054671,"threshold_uncertainty_score":0.027897894},"labels":[],"label_agreement":null},{"id":"W1999280643","doi":"10.1310/hct0705-251","title":"Infection Rates in HIV-HCV Patients Treated with Interferon Are Similar to Those in HCV Mono-Infection and Not Related to Neutropenia","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Neutropenia; Human immunodeficiency virus (HIV); Interferon; Infection rate; Internal medicine; Immunology; Ribavirin; Hepatitis C virus; Virus; Surgery; Chemotherapy","score_opus":0.17411955403498594,"score_gpt":0.47486931815223443,"score_spread":0.3007497641172485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999280643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991371,0.0004229428,0.000043263804,0.000026188372,0.000002915694,0.000013673999,0.000055335353,0.0000016605015,0.00029696224],"genre_scores_gemma":[0.9995529,0.00011401824,0.000086905944,0.000021710266,0.000005931307,0.000010628778,0.00012121354,6.370185e-7,0.00008596491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994024,0.00033051922,0.000056253328,0.000045408895,0.00009918376,0.000066246976],"domain_scores_gemma":[0.9975395,0.00077798095,0.0012803181,0.000092837705,0.00009591449,0.00021331717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083217537,0.000126782,0.00027395666,0.0002808625,0.0002064337,0.00031335346,0.000106384425,0.00033314788,0.0015250985],"category_scores_gemma":[0.003764362,0.00014141203,0.00020498814,0.00020573947,0.00017670335,0.00018320334,0.00013363812,0.00033149883,0.00015117954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002878995,0.00023347007,0.9844624,0.000048531132,0.0001107942,0.000276729,0.00011453238,0.00014922247,0.0017036394,0.000047001304,0.00017925285,0.009795395],"study_design_scores_gemma":[0.0002157851,0.0015624207,0.99571145,0.00002001609,0.00005290917,0.0012095545,0.00008933571,0.00024497564,0.00053904206,0.000047274163,0.00029913345,0.000008027801],"about_ca_topic_score_codex":0.00072725816,"about_ca_topic_score_gemma":0.0012927842,"teacher_disagreement_score":0.0015250985,"about_ca_system_score_codex":0.0002162989,"about_ca_system_score_gemma":0.00020338198,"threshold_uncertainty_score":0.005101979},"labels":[],"label_agreement":null},{"id":"W2003082239","doi":"10.1310/hct1503-116","title":"Factors Associated With Study Attrition Among HIV-Infected Risky Drinkers in St. Petersburg, Russia","year":2014,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV, Drug Use, Sexual Risk","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute on Drug Abuse; National Institute on Alcohol Abuse and Alcoholism; McMaster University","keywords":"Medicine; Attrition; Binge drinking; Logistic regression; Proportional hazards model; Demography; Hazard ratio; Human immunodeficiency virus (HIV); Psychiatry; Gerontology; Internal medicine; Environmental health; Confidence interval; Family medicine; Poison control; Suicide prevention","score_opus":0.33629799678827704,"score_gpt":0.47530698100558566,"score_spread":0.13900898421730862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003082239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975885,0.00093278236,0.00027227006,0.00049910985,0.000014834728,0.000052007523,0.0003282522,0.000005570126,0.0003066091],"genre_scores_gemma":[0.9992005,0.00021945949,0.00014164169,0.00008276555,0.000012176548,0.00007218457,0.00017290503,0.0000021219523,0.00009627681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523747,0.0030054708,0.00045454674,0.00037330887,0.00048548257,0.0004437784],"domain_scores_gemma":[0.9911273,0.0030315144,0.004316829,0.0005389654,0.000503332,0.00048210874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0089480085,0.00012541654,0.0005025276,0.000631755,0.00085367064,0.00080012856,0.0005262724,0.00037181727,0.0010883481],"category_scores_gemma":[0.014738581,0.00021757511,0.0004966266,0.00086606556,0.00036263483,0.00045915772,0.000816393,0.00055346586,0.00010611726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023733734,0.000029687277,0.99390596,0.00007416729,0.000080936,0.00006200882,0.0005884015,0.000057235236,0.00009626,0.00006880639,0.0002817615,0.0045173806],"study_design_scores_gemma":[0.000016809525,0.000091304384,0.9982828,0.000094766234,0.00007255503,0.0000837404,0.0005224597,0.00032233316,0.00006517413,0.00008515887,0.00035890838,0.0000039647316],"about_ca_topic_score_codex":0.010415439,"about_ca_topic_score_gemma":0.013571174,"teacher_disagreement_score":0.010415439,"about_ca_system_score_codex":0.0006951967,"about_ca_system_score_gemma":0.0019491396,"threshold_uncertainty_score":0.047322154},"labels":[],"label_agreement":null},{"id":"W2003655730","doi":"10.1310/b6t0-n98j-1j3m-eqpk","title":"Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens","year":2002,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Abacavir; Mycophenolate; Internal medicine; Salvage therapy; Human immunodeficiency virus (HIV); Pharmacology; Viral load; Immunology; Antiretroviral therapy; Chemotherapy; Transplantation","score_opus":0.2900278795689513,"score_gpt":0.4613258626269102,"score_spread":0.1712979830579589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003655730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844998,0.0027353184,0.0010448683,0.0012515482,0.00021792103,0.00014008142,0.00011718414,0.00006399672,0.009929302],"genre_scores_gemma":[0.9966685,0.00084574084,0.00041997255,0.00059380353,0.00037606442,0.00004196792,0.000109378496,0.000018939783,0.0009257155],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9985837,0.0004030925,0.00016934783,0.00020705322,0.00023639096,0.00040033224],"domain_scores_gemma":[0.9941367,0.002717432,0.0011973553,0.00057463464,0.0002739146,0.0011000053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008011058,0.001459228,0.0010155481,0.0013686958,0.0024920248,0.001719351,0.0010911288,0.0046020583,0.0043130103],"category_scores_gemma":[0.010084416,0.0008726664,0.0011731933,0.0010684823,0.00148842,0.001321067,0.0009014373,0.0029289953,0.0014668292],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003546937,0.00043331366,0.043751527,0.000058575555,0.00004743991,0.9484406,0.00039007768,0.00016410806,0.00049766887,0.00018539975,0.00081167824,0.004864954],"study_design_scores_gemma":[0.00010006518,0.00056864787,0.0075414046,0.000020186317,0.000028082488,0.9897385,0.00016582002,0.00024320792,0.00043217544,0.00007743913,0.0010719227,0.000012530563],"about_ca_topic_score_codex":0.0016102707,"about_ca_topic_score_gemma":0.001504417,"teacher_disagreement_score":0.0046020583,"about_ca_system_score_codex":0.0013071807,"about_ca_system_score_gemma":0.0012099659,"threshold_uncertainty_score":0.014428496},"labels":[],"label_agreement":null},{"id":"W2006674154","doi":"10.1310/hct1302-111","title":"Impact of Baseline Virologic, Immunologic, and Demographic Characteristics on Virologic Responses in the Gemini Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Division of Chemistry","keywords":"Medicine; Baseline (sea); Immunology; Internal medicine","score_opus":0.2652432090282322,"score_gpt":0.4965311565393695,"score_spread":0.23128794751113735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006674154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685836,0.0019175148,0.00021051707,0.0001452865,0.000023217102,0.000055837034,0.00021141359,0.000017460727,0.00056046306],"genre_scores_gemma":[0.9991008,0.00014609752,0.00021851373,0.000074263284,0.000032471395,0.000029643576,0.00020060745,0.0000062391523,0.00019144652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940454,0.0049511185,0.00015677261,0.00031449317,0.00033937464,0.00019279479],"domain_scores_gemma":[0.9958047,0.0022531427,0.0008724002,0.00046516783,0.00021052854,0.00039412972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011054678,0.00062182086,0.001191755,0.0002348018,0.00025348944,0.00064677134,0.0003395715,0.0003994335,0.0010126734],"category_scores_gemma":[0.00655173,0.00019783984,0.0013174515,0.00029743934,0.00023391137,0.0004875617,0.0003078866,0.0007908055,0.00012897378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.345444,0.0015396572,0.5725144,0.00068029755,0.006423212,0.00019677394,0.00037503103,0.0010971135,0.0062424606,0.00014595201,0.0017146544,0.063626505],"study_design_scores_gemma":[0.00515812,0.03544767,0.9461756,0.00007514674,0.004489841,0.00024817316,0.00021927331,0.002818261,0.002595551,0.00012613152,0.0026147934,0.000031430496],"about_ca_topic_score_codex":0.0004512042,"about_ca_topic_score_gemma":0.0012458309,"teacher_disagreement_score":0.011054678,"about_ca_system_score_codex":0.0002913212,"about_ca_system_score_gemma":0.00044938165,"threshold_uncertainty_score":0.058463454},"labels":[],"label_agreement":null},{"id":"W2013976388","doi":"10.1310/p52n-kxjh-1945-ux7x","title":"The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom","year":2000,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Life expectancy; Nucleoside analogue; Quality-adjusted life year; Cost effectiveness; Clinical trial; Quality of life (healthcare); Observational study; Population; Antiretroviral therapy; Human immunodeficiency virus (HIV); Intensive care medicine; Viral load; Internal medicine; Nucleoside; Family medicine; Environmental health; Risk analysis (engineering)","score_opus":0.2806454061765764,"score_gpt":0.465997805989622,"score_spread":0.18535239981304558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013976388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94289154,0.03621373,0.0052772206,0.0040238146,0.00016869702,0.00025339765,0.0015024106,0.000036558733,0.009632641],"genre_scores_gemma":[0.9960551,0.0026271988,0.0007085374,0.00009402342,0.000007486052,0.000038312992,0.00015967905,0.000002229159,0.00030743857],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9977723,0.0016775418,0.00011307964,0.0000707127,0.00024373477,0.0001226458],"domain_scores_gemma":[0.9962619,0.0029064503,0.00041848372,0.000044453293,0.00021648519,0.00015214577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020265442,0.00034850673,0.0005561522,0.00052624603,0.0002334655,0.001123809,0.00034206445,0.0007099897,0.002419287],"category_scores_gemma":[0.011686993,0.00022121571,0.0008803764,0.0004416102,0.00032630944,0.000714351,0.0006714797,0.0005896141,0.00011283299],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0096795885,0.00043545006,0.1109178,0.004288172,0.001999173,0.0015334749,0.00035304148,0.6762639,0.0014013107,0.010879157,0.0067592855,0.1754896],"study_design_scores_gemma":[0.0044873552,0.008087969,0.22741464,0.006015248,0.003948206,0.004293379,0.0011541112,0.71000385,0.0034519248,0.015892286,0.014981306,0.00026970208],"about_ca_topic_score_codex":0.040045995,"about_ca_topic_score_gemma":0.032234948,"teacher_disagreement_score":0.040045995,"about_ca_system_score_codex":0.004557455,"about_ca_system_score_gemma":0.0020184568,"threshold_uncertainty_score":0.079625845},"labels":[],"label_agreement":null},{"id":"W2015215132","doi":"10.1310/hct1001-63","title":"HIV Essentials By Paul E. Sax, Calvin J. Cohen, and Daniel R. Kuritzkes. Jones &amp; Bartlett Publishers, 2008, 200 pp","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Human immunodeficiency virus (HIV); Classics; Family medicine; Art","score_opus":0.1527906471076678,"score_gpt":0.46098054972833885,"score_spread":0.30818990262067103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015215132","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026275156,0.7200129,0.002206596,0.15175368,0.032313764,0.00011489773,0.0014729829,0.00054186257,0.09132059],"genre_scores_gemma":[0.0040060505,0.47940052,0.0037339767,0.053216934,0.021317815,0.0002527635,0.0013688768,0.00069397135,0.4360091],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983203,0.00043887438,0.00017017777,0.00016960956,0.0008121233,0.00008895406],"domain_scores_gemma":[0.99152726,0.0038152332,0.0008183419,0.00024899805,0.002282783,0.0013074927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042399885,0.0013578223,0.001099677,0.0026797939,0.00093768,0.003534356,0.0010773147,0.002135323,0.07319789],"category_scores_gemma":[0.012342876,0.001003228,0.00060431875,0.002706,0.0010685663,0.004215392,0.0016226232,0.006163691,0.07803322],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011758516,0.000004815396,0.000039510032,0.00013141043,0.0000023418422,0.000011379811,0.000037051912,0.000011006333,0.0000339256,0.000813779,0.9797555,0.019147547],"study_design_scores_gemma":[0.000009278426,0.000012890839,0.0003227194,0.00065300346,0.0000063953676,0.00016001507,0.00008090283,0.000036280144,0.000049113256,0.0013487773,0.9973138,0.00000694584],"about_ca_topic_score_codex":0.0053373594,"about_ca_topic_score_gemma":0.013012485,"teacher_disagreement_score":0.07319789,"about_ca_system_score_codex":0.0017808498,"about_ca_system_score_gemma":0.0033809752,"threshold_uncertainty_score":0.24487132},"labels":[],"label_agreement":null},{"id":"W2020067315","doi":"10.1310/95ve-a6kj-wrq0-1f8y","title":"Mild to Moderate Symptoms Do Not Correlate with Lactate Levels in HIV-Positive Patients on Nucleoside Reverse Transcriptase Inhibitors","year":2006,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Reverse transcriptase; Nucleoside Reverse Transcriptase Inhibitor; Human immunodeficiency virus (HIV); Nucleoside; Reverse-transcriptase inhibitor; Pharmacology; Internal medicine; Virology; Antiretroviral therapy; Viral load; RNA; Biochemistry","score_opus":0.11369221170588129,"score_gpt":0.4102275988494202,"score_spread":0.29653538714353894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020067315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999343,0.00022903779,0.00003755492,0.00004495079,0.000009040453,0.0000068900354,0.00006814107,0.0000018753461,0.0002596435],"genre_scores_gemma":[0.9997738,0.000048948208,0.000032070755,0.000024823043,0.000009323106,0.0000028620111,0.000071669245,6.8503914e-7,0.00003588074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994247,0.00018480171,0.00010875521,0.00008386209,0.000112795846,0.000085027874],"domain_scores_gemma":[0.996151,0.0009987957,0.0017289487,0.00011889243,0.000334585,0.0006677267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006476818,0.00029061156,0.00038809775,0.0005352298,0.00037516773,0.00071676663,0.0002337515,0.0005105046,0.001896947],"category_scores_gemma":[0.0055911974,0.00028482053,0.00031062088,0.00056329294,0.00034037986,0.00047152885,0.00038343397,0.0005732958,0.00026059334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009531047,0.000024256735,0.9990664,0.000007937371,0.000017109798,0.000060840324,0.00003540344,0.000015865562,0.00013415229,0.0000037339657,0.00003189278,0.00050714053],"study_design_scores_gemma":[0.000016487027,0.0003305327,0.9983353,0.000012675133,0.000029542267,0.0006420695,0.00020987848,0.00021307505,0.00006695739,0.000021482476,0.00011751892,0.000004607928],"about_ca_topic_score_codex":0.001097401,"about_ca_topic_score_gemma":0.0013408189,"teacher_disagreement_score":0.001896947,"about_ca_system_score_codex":0.00017201989,"about_ca_system_score_gemma":0.00025251877,"threshold_uncertainty_score":0.0063459277},"labels":[],"label_agreement":null},{"id":"W2023680960","doi":"10.1310/hct1106-340","title":"Effect of Gender and Calendar Year on Time to and Duration of Virologic Suppression Among Antiretroviral-Naïve HIV-Infected Individuals Initiating Combination Antiretroviral Therapy","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Maple Leaf Medical Clinic; Ontario HIV Treatment Network; St. Michael's Hospital; Public Health Ontario; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Health Canada; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Interquartile range; Hazard ratio; Regimen; Proportional hazards model; Viral load; Antiretroviral therapy; Cohort; Internal medicine; Human immunodeficiency virus (HIV); Cohort study; Confidence interval; Immunology","score_opus":0.09042930505775788,"score_gpt":0.447746397133398,"score_spread":0.3573170920756401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023680960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950681,0.0021655369,0.0001191364,0.00024846525,0.00004469162,0.000009843884,0.0013261652,0.000008715818,0.0010093652],"genre_scores_gemma":[0.9987582,0.00038827525,0.000057775622,0.00004624572,0.000015492767,0.0000040322443,0.00038131152,0.000003474262,0.00034520647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994861,0.00014164028,0.000027879669,0.00008429745,0.00011582304,0.00014425287],"domain_scores_gemma":[0.99748576,0.00056047837,0.0011012581,0.00015263661,0.00022040102,0.00047946427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010371805,0.00025542933,0.00026296088,0.00041791692,0.00035805156,0.00047057538,0.00035277527,0.00027249657,0.0020783886],"category_scores_gemma":[0.0045365663,0.00018417051,0.0006790759,0.00049373676,0.00020679104,0.00027449182,0.00029604035,0.00035846123,0.00016615757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006258752,0.000017897737,0.9967014,0.000009452632,0.000076029515,0.000037417238,0.000046833455,0.000047126563,0.00010415338,0.000011454397,0.00019880685,0.002123638],"study_design_scores_gemma":[0.000009092059,0.000093724586,0.99927396,0.000009649434,0.000041856467,0.000065576234,0.000046067766,0.00016877087,0.00003184655,0.000011058226,0.00024570353,0.0000026310963],"about_ca_topic_score_codex":0.049786855,"about_ca_topic_score_gemma":0.08130975,"teacher_disagreement_score":0.049786855,"about_ca_system_score_codex":0.00064108055,"about_ca_system_score_gemma":0.001112459,"threshold_uncertainty_score":0.098994136},"labels":[],"label_agreement":null},{"id":"W2023936662","doi":"10.1310/hct1306-357","title":"Physician Attitudes Regarding Pregnancy, Fertility Care, and Assisted Reproductive Technologies for HIV-Infected Individuals and Couples","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Reproductive Health and Technologies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; University of British Columbia Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto; St. Michael's Hospital","funders":"","keywords":"Fertility; Medicine; Assisted reproductive technology; Family medicine; Pregnancy; Population; Logistic regression; Reproductive medicine; Reproductive health; Fertility clinic; Gynecology; Infertility; Environmental health","score_opus":0.2701846422825666,"score_gpt":0.4840508541485525,"score_spread":0.21386621186598587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023936662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656063,0.00044006112,0.00005030086,0.0006077116,0.00000807005,0.00001127363,0.000058548347,0.0000020019531,0.0022614307],"genre_scores_gemma":[0.99857044,0.00056528795,0.00011136966,0.00029223898,0.000012518828,0.0000054394945,0.00005282983,4.5147812e-7,0.00038948833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99937797,0.00021149928,0.000033943994,0.000035051227,0.00024654812,0.0000949906],"domain_scores_gemma":[0.9968299,0.0009372671,0.00095582596,0.000044255146,0.0004784383,0.0007542768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095363165,0.000082054656,0.000075970296,0.00030241354,0.0005742107,0.00033921996,0.00014415907,0.00026513802,0.0022832626],"category_scores_gemma":[0.004705033,0.00007742742,0.00012433984,0.00028364503,0.00040874662,0.00021302074,0.00019035161,0.00025073887,0.00012559463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030539613,0.00004562461,0.9900539,0.000034820638,0.000014276466,0.000082750805,0.0014964814,0.000054673976,0.00021192429,0.000032938635,0.00043960314,0.007502346],"study_design_scores_gemma":[0.0000051235124,0.00010473003,0.9965108,0.00003875148,0.000012507264,0.00033756543,0.0018098498,0.000096088355,0.00007007009,0.000017260074,0.000994029,0.0000032825897],"about_ca_topic_score_codex":0.08450336,"about_ca_topic_score_gemma":0.14680077,"teacher_disagreement_score":0.08450336,"about_ca_system_score_codex":0.0009078312,"about_ca_system_score_gemma":0.0016378384,"threshold_uncertainty_score":0.16802299},"labels":[],"label_agreement":null},{"id":"W2034769242","doi":"10.1310/3hhb-59up-93mm-aaxy","title":"HIV Lipodystrophy: A Review","year":2000,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Lipodystrophy; Medicine; Stavudine; Diabetes mellitus; Hyperlipidemia; Metabolic syndrome; Antiretroviral therapy; Bioinformatics; Human immunodeficiency virus (HIV); Intensive care medicine; Immunology; Endocrinology; Viral load; Biology","score_opus":0.5069420519687867,"score_gpt":0.6030165185156607,"score_spread":0.09607446654687402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034769242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000081635924,0.99888796,0.00004494776,0.00011173172,0.00016412807,0.000009552898,0.000017111051,0.000004777371,0.0006782064],"genre_scores_gemma":[0.0002824229,0.99898297,0.00015467561,0.000104551415,0.00012145051,0.000009929252,0.00002180792,6.2875336e-7,0.00032157174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997887,0.00004174923,0.00004665643,0.000028865392,0.000079801735,0.000014202929],"domain_scores_gemma":[0.99965584,0.00016507805,0.000066753935,0.000007820639,0.000073791845,0.000030740317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050094095,0.0010898671,0.0021603536,0.0037517583,0.00034896753,0.0011878856,0.0009843525,0.0009372722,0.0071011134],"category_scores_gemma":[0.00073629554,0.00035080878,0.0004880069,0.005325715,0.00030680595,0.0014817223,0.00056340673,0.0009791063,0.003061747],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098806646,0.00013036659,0.00019556255,0.04641248,0.00014378091,0.0004911287,0.00008759846,0.00027298907,0.0007541917,0.0010815595,0.04349226,0.9068393],"study_design_scores_gemma":[0.000052089177,0.00014750783,0.0015576397,0.018286092,0.00033710213,0.0028676726,0.00014912439,0.000078704164,0.00021245099,0.0011421961,0.97514784,0.000021599724],"about_ca_topic_score_codex":0.0015692777,"about_ca_topic_score_gemma":0.0031906473,"teacher_disagreement_score":0.0071011134,"about_ca_system_score_codex":0.00059202395,"about_ca_system_score_gemma":0.0014419333,"threshold_uncertainty_score":0.02375561},"labels":[],"label_agreement":null},{"id":"W2035341996","doi":"10.1310/hct1002-76","title":"Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Clair College","funders":"GlaxoSmithKline","keywords":"Medicine; Abacavir; Lopinavir/ritonavir; Lopinavir; Ritonavir; Interquartile range; Lamivudine; Adverse effect; Viral load; Internal medicine; Gastroenterology; Pharmacology; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Virus; Chronic hepatitis","score_opus":0.12890663139448505,"score_gpt":0.4384300801451987,"score_spread":0.30952344875071364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035341996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964359,0.0022920424,0.00010246674,0.00009232219,0.000044138622,0.00022345009,0.00020555957,0.000016295648,0.00058789516],"genre_scores_gemma":[0.9970933,0.0007019964,0.00031011217,0.00014009653,0.0000871107,0.0003168175,0.00033120916,0.0000060660063,0.0010132754],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990969,0.00050881575,0.00007516619,0.00013673598,0.000082729974,0.00009967108],"domain_scores_gemma":[0.99842536,0.00038508084,0.0004835107,0.000111113106,0.0000993471,0.0004956244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017126789,0.00077528536,0.0019912014,0.00027015829,0.0002779223,0.0007666207,0.0006386851,0.0008773617,0.0029687565],"category_scores_gemma":[0.0017184903,0.00048689079,0.0013239558,0.00023878907,0.00059228385,0.0010921332,0.0003668376,0.0016125783,0.0006004282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94655883,0.011390461,0.002684293,0.00043811128,0.00079784397,0.0000660996,0.00009085446,0.0006789332,0.0072492645,0.00004524251,0.00036981842,0.029630145],"study_design_scores_gemma":[0.41140172,0.55913025,0.022186022,0.00008049293,0.0010288878,0.00018683834,0.00007045146,0.0011650167,0.0033717644,0.00011975766,0.0012022081,0.000056536504],"about_ca_topic_score_codex":0.0005274965,"about_ca_topic_score_gemma":0.0015786062,"teacher_disagreement_score":0.0029687565,"about_ca_system_score_codex":0.0006807208,"about_ca_system_score_gemma":0.0008173668,"threshold_uncertainty_score":0.009931505},"labels":[],"label_agreement":null},{"id":"W2037740736","doi":"10.1310/hct1304-179","title":"A Pilot, Prospective, Open-Label Simplification Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Once-Daily Lopinavir-Ritonavir Monotherapy in HIV-HCV Coinfected Patients: The MONOCO Study","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia; Ottawa Hospital; Abbott (Canada); University of Ottawa","funders":"Ontario HIV Treatment Network; Abbott Laboratories","keywords":"Medicine; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Prospective cohort study; Lopinavir/ritonavir; Internal medicine; Viral load; Pharmacology; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology","score_opus":0.28697042477038737,"score_gpt":0.5185631127525557,"score_spread":0.23159268798216837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037740736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962603,0.00019064461,0.00033102994,0.000071748065,0.000026496578,0.0025112408,0.000207564,0.000018747865,0.00038227206],"genre_scores_gemma":[0.992274,0.00023143468,0.0017257135,0.00034161287,0.00017354482,0.0036918796,0.00071540935,0.0000110337305,0.0008353182],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99806005,0.0011974908,0.00010266666,0.00021529717,0.00020511048,0.0002193192],"domain_scores_gemma":[0.99600166,0.00076262554,0.0011398904,0.00056306995,0.00031014628,0.0012227024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040628244,0.0015728133,0.0021108678,0.00045155417,0.00080036116,0.00073673244,0.00077306473,0.000985457,0.0033065197],"category_scores_gemma":[0.0031305216,0.0007301185,0.0012466492,0.0003482699,0.0012763513,0.0008840477,0.0007681487,0.0015756651,0.0006520306],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80257267,0.11906076,0.028542819,0.00041247346,0.00091742136,0.00024913577,0.0006431154,0.0007006129,0.015397192,0.0001242321,0.00092288357,0.030456683],"study_design_scores_gemma":[0.23487625,0.72573817,0.036253773,0.000013515883,0.00032179517,0.00013294081,0.00007912628,0.0005916052,0.0010528099,0.00007999191,0.00082677265,0.000033160704],"about_ca_topic_score_codex":0.0010465223,"about_ca_topic_score_gemma":0.0014616471,"teacher_disagreement_score":0.0040628244,"about_ca_system_score_codex":0.00076144,"about_ca_system_score_gemma":0.0013595673,"threshold_uncertainty_score":0.02148658},"labels":[],"label_agreement":null},{"id":"W2048157797","doi":"10.1310/hct1202-89","title":"Ethnicity and Gender Differences in Lipodystrophy of HIV-Positive Individuals Taking Antiretroviral Therapy in Ontario, Canada","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston General Hospital; Sunnybrook Health Science Centre; St. Michael's Hospital; Women's College Hospital; Ontario HIV Treatment Network; Canadians Living with HIV; Health Sciences Centre; University Health Network; University of Toronto","funders":"Division of Undergraduate Education","keywords":"Lipodystrophy; Medicine; Lipoatrophy; Multicenter AIDS Cohort Study; Internal medicine; Cross-sectional study; Logistic regression; Ethnic group; Cohort; Prospective cohort study; Univariate analysis; Multivariate analysis; Antiretroviral therapy; Human immunodeficiency virus (HIV); Immunology; Pathology; Viral load","score_opus":0.3563934803590323,"score_gpt":0.43659283879343025,"score_spread":0.08019935843439796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048157797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996847,0.0005221662,0.000039609986,0.0001722561,0.000008567028,0.000014777968,0.000804608,0.0000023009366,0.0015888556],"genre_scores_gemma":[0.9988813,0.0002667643,0.000046924517,0.000050199887,0.0000032253163,0.000006460295,0.0002943632,0.000001868287,0.00044887426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995783,0.00003632748,0.000026989057,0.000054206463,0.00014972294,0.00015458118],"domain_scores_gemma":[0.999204,0.000059871636,0.00026230732,0.000020536017,0.00024699984,0.00020626729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035313683,0.00019986667,0.00029338038,0.0008230872,0.0021089753,0.00075146207,0.0004972862,0.0002637752,0.0021501244],"category_scores_gemma":[0.0013307654,0.00021311727,0.00036694095,0.0015843704,0.00048289757,0.00024408686,0.00046278507,0.00029151342,0.00015175206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034402598,0.0000078733265,0.9976829,0.0000093075305,0.000015030627,0.00006574212,0.0006563869,0.000015559866,0.00011702923,0.000028021786,0.00019902312,0.0011687197],"study_design_scores_gemma":[0.0000022205375,0.000007376304,0.9985953,0.0000153976,0.00000855764,0.00006567509,0.0009323077,0.000047809866,0.000015772579,0.000010654443,0.00029622068,0.0000027173196],"about_ca_topic_score_codex":0.9593875,"about_ca_topic_score_gemma":0.97871715,"teacher_disagreement_score":0.04061252,"about_ca_system_score_codex":0.006544298,"about_ca_system_score_gemma":0.0067708865,"threshold_uncertainty_score":0.081703305},"labels":[],"label_agreement":null},{"id":"W2048476931","doi":"10.1310/cwd3-dr4k-7ee0-7abl","title":"The Efficacy of Calcium Carbonate in the Treatment of Protease Inhibitor-Induced Persistent Diarrhea in HIV-Infected Patients","year":2004,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Pharmacists Association; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Diarrhea; Internal medicine; Visual analogue scale; Calcium carbonate; Calcium; Nelfinavir; Prospective cohort study; Gastroenterology; Human immunodeficiency virus (HIV); Surgery; Immunology; Antiretroviral therapy; Viral load","score_opus":0.17971267512180408,"score_gpt":0.4497504274225439,"score_spread":0.2700377523007398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048476931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978302,0.020034313,0.000103963845,0.00028221382,0.000051649877,0.00028101576,0.00013036904,0.000010975499,0.0008035167],"genre_scores_gemma":[0.9939069,0.004784992,0.0005324318,0.00018755066,0.00009191425,0.00012521383,0.00017146821,0.0000027834822,0.00019670048],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990889,0.00054841297,0.000109899964,0.000053084685,0.00014720511,0.000052482796],"domain_scores_gemma":[0.9976808,0.0010112674,0.0007983679,0.00006002281,0.00016116549,0.00028836378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013926041,0.00020468736,0.0009213857,0.00031613567,0.0002775852,0.00054823124,0.00035317132,0.0005556271,0.00094462396],"category_scores_gemma":[0.0037929167,0.00013965352,0.00057327363,0.00048326596,0.00031776467,0.0003409789,0.00024752345,0.00071797404,0.00007516416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43736842,0.014297209,0.10936821,0.00612979,0.002774454,0.00031007183,0.00040422386,0.00072308414,0.012402368,0.00015171412,0.0014118645,0.41465855],"study_design_scores_gemma":[0.11524679,0.49751803,0.3713995,0.0010253986,0.0028693008,0.00093985064,0.00036470316,0.0017825131,0.0044450774,0.00017351408,0.004167423,0.00006791145],"about_ca_topic_score_codex":0.0010330944,"about_ca_topic_score_gemma":0.0018688757,"teacher_disagreement_score":0.0013926041,"about_ca_system_score_codex":0.00033830456,"about_ca_system_score_gemma":0.0006325693,"threshold_uncertainty_score":0.007364869},"labels":[],"label_agreement":null},{"id":"W2050657418","doi":"10.1310/hct1101-39","title":"A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy","year":2010,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"National Center for Research Resources; U.S. Public Health Service; National Institutes of Health; Amgen; National Institute of Diabetes and Digestive and Kidney Diseases; Gilead Sciences; National Institute of Allergy and Infectious Diseases; Medical Research Council; ACT Government; Bristol-Myers Squibb; GlaxoSmithKline; National Health and Medical Research Council","keywords":"Pioglitazone; Rosiglitazone; Medicine; Placebo; Thiazolidinedione; Stavudine; Internal medicine; Lipoatrophy; Body mass index; Zidovudine; Urology; Endocrinology; Gastroenterology; Pharmacology; Diabetes mellitus; Human immunodeficiency virus (HIV); Antiretroviral therapy; Type 2 diabetes; Viral load; Insulin; Immunology; Pathology","score_opus":0.6418827890290362,"score_gpt":0.5873134464127776,"score_spread":0.054569342616258565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050657418","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04861517,0.9457967,0.0018146647,0.0005147525,0.0005449856,0.00048181647,0.0014798768,0.00011281272,0.0006391946],"genre_scores_gemma":[0.7598747,0.23047067,0.0042193555,0.00138488,0.00046008424,0.0010511155,0.00185673,0.00007801426,0.00060444354],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9815493,0.012003916,0.0030083635,0.001933435,0.0011270056,0.00037803297],"domain_scores_gemma":[0.98217344,0.013346885,0.0027191795,0.0007228736,0.0007431073,0.00029446054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017329767,0.0034120732,0.0165198,0.0042648856,0.00083365245,0.0038057794,0.001803338,0.0024933692,0.0036781123],"category_scores_gemma":[0.030615797,0.0014693751,0.04215649,0.0045519113,0.0007534885,0.0013010411,0.0011589812,0.0024747294,0.00027930198],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014073768,0.000037515423,0.004629152,0.026674176,0.9480436,0.000091975366,0.000022273922,0.0007152434,0.00027058573,0.000052623338,0.0003054659,0.0050836126],"study_design_scores_gemma":[0.002933981,0.00040047115,0.0036299361,0.0013794682,0.99063057,0.000055649194,0.00001582385,0.00025402082,0.00010364998,0.000105502244,0.0004798258,0.000011197742],"about_ca_topic_score_codex":0.0039960947,"about_ca_topic_score_gemma":0.007566742,"teacher_disagreement_score":0.017329767,"about_ca_system_score_codex":0.001960634,"about_ca_system_score_gemma":0.0016618179,"threshold_uncertainty_score":0.09164965},"labels":[],"label_agreement":null},{"id":"W2050892293","doi":"10.1310/hct1203-151","title":"Treatment Durability, Effectiveness, and Safety with Atazanavir/Ritonavir-Based HAART Regimen in Treatment-Naïve HIV-lnfected Patients","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Heart Institute; Sunnybrook Health Science Centre; McGill University; Centre Hospitalier de l’Université de Montréal; Bristol-Myers Squibb (Canada); Maple Leaf Medical Clinic; Université de Montréal","funders":"","keywords":"Medicine; Ritonavir; Discontinuation; Atazanavir; Viral load; Regimen; Internal medicine; Human immunodeficiency virus (HIV); Gastroenterology; Antiretroviral therapy; Immunology","score_opus":0.1576212044445199,"score_gpt":0.40258714999977185,"score_spread":0.24496594555525195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050892293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989035,0.0007516451,0.000029653156,0.000026934957,0.000002118663,0.00000713395,0.00006454548,0.0000016092671,0.00021283005],"genre_scores_gemma":[0.9996126,0.00012971438,0.00005470903,0.000027274586,0.000008033172,0.0000039598867,0.0001108941,6.5502996e-7,0.000052195013],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99946624,0.00015704834,0.00006919396,0.000072970906,0.00015651861,0.00007797036],"domain_scores_gemma":[0.9983328,0.00041378135,0.0008365906,0.000066210094,0.00017057588,0.0001800407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086109916,0.00009903933,0.00030623638,0.00022881976,0.000375274,0.00057000027,0.00018628348,0.0002475053,0.0005274578],"category_scores_gemma":[0.0037144828,0.000085969245,0.0002854733,0.00028650314,0.00019736636,0.00030881053,0.00010048081,0.00028605334,0.00007606279],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011734096,0.00010821575,0.9838304,0.00004019861,0.000078181096,0.00025038834,0.00015479268,0.00013297265,0.00068290636,0.00001552472,0.00008938735,0.0134437615],"study_design_scores_gemma":[0.00008259374,0.0018343176,0.994935,0.0000259326,0.00008876857,0.0015393739,0.00013986634,0.00038634913,0.00039635698,0.000014565959,0.00054909085,0.000007820709],"about_ca_topic_score_codex":0.0067036827,"about_ca_topic_score_gemma":0.008325572,"teacher_disagreement_score":0.0067036827,"about_ca_system_score_codex":0.0007444233,"about_ca_system_score_gemma":0.00052245735,"threshold_uncertainty_score":0.013329327},"labels":[],"label_agreement":null},{"id":"W2058157173","doi":"10.1310/a9b9-rqd7-u8ka-503u","title":"Comparison of Prognostic Importance of Latest CD4+ Cell Count and HIV RNA Levels in Patients with Advanced HIV Infection on Highly Active Antiretroviral Therapy","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Viral load; Medicine; Hazard ratio; Regimen; Antiretroviral therapy; Internal medicine; Immunology; Human immunodeficiency virus (HIV); Virology; Gastroenterology; Confidence interval","score_opus":0.10527197483588475,"score_gpt":0.41841108543661076,"score_spread":0.313139110600726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058157173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99920195,0.0004895274,0.00003846847,0.000045671768,0.000004885729,0.0000024974406,0.0000814129,0.0000014493294,0.00013420543],"genre_scores_gemma":[0.9996525,0.00009490087,0.00003661571,0.000015813297,0.000021793856,0.0000017739422,0.0001456083,6.789507e-7,0.000030227517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99950755,0.00021505354,0.000041800828,0.000074949654,0.000086785876,0.00007391289],"domain_scores_gemma":[0.9955705,0.0023368923,0.00114268,0.000128489,0.00016673999,0.00065475254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009412926,0.00032748876,0.0005306415,0.00045308983,0.00030981848,0.0006290765,0.0003285567,0.0006224568,0.0011648507],"category_scores_gemma":[0.0043607606,0.00016964854,0.00039512216,0.00068335223,0.00035334748,0.00047177591,0.00032389685,0.0005870381,0.00013771554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093225954,0.000026831694,0.9969433,0.0000104629835,0.0000661573,0.00005705341,0.000022805296,0.00010396834,0.00010178002,0.000007760288,0.00004897754,0.0016786739],"study_design_scores_gemma":[0.00005546216,0.00044220925,0.99806684,0.000008117261,0.000063935506,0.0004298643,0.00007886763,0.00062540954,0.000072104456,0.000044637323,0.00010596477,0.0000065151544],"about_ca_topic_score_codex":0.00087174604,"about_ca_topic_score_gemma":0.00086381234,"teacher_disagreement_score":0.0011648507,"about_ca_system_score_codex":0.00017412611,"about_ca_system_score_gemma":0.00019376444,"threshold_uncertainty_score":0.0049780607},"labels":[],"label_agreement":null},{"id":"W2063088890","doi":"10.1310/hct1205-275","title":"Vitamin D Supplementation Does Not Increase Immunogenicity of Seasonal Influenza Vaccine in HIV-Infected Adults","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Vitamin D Research Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HIV Legal Network; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Immunogenicity; Medicine; Seroconversion; Influenza vaccine; Vitamin; Human immunodeficiency virus (HIV); Population; Virology; Immunology; Physiology; Internal medicine; Antibody; Environmental health; Vaccination","score_opus":0.18292417760403892,"score_gpt":0.46779409425391555,"score_spread":0.2848699166498766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063088890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98767847,0.010247272,0.00010929578,0.00055476296,0.00015264539,0.00015718058,0.00017322098,0.000013470812,0.00091373536],"genre_scores_gemma":[0.99558145,0.0030676052,0.00025546912,0.000458682,0.00012597142,0.0000697406,0.00011315354,0.0000037969287,0.0003241608],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99859554,0.00094003824,0.00014605133,0.000094202194,0.00013527006,0.00008891657],"domain_scores_gemma":[0.99736965,0.0015785818,0.000531992,0.00015708193,0.000120870376,0.00024184809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002465342,0.00028215186,0.0011260456,0.00023277271,0.0002784018,0.000512676,0.00038906085,0.0012435864,0.0017576105],"category_scores_gemma":[0.005189147,0.00036110813,0.0011703143,0.00021740404,0.00043565527,0.00039387622,0.00024150735,0.0009774109,0.00019444921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.79099053,0.009568694,0.025719123,0.0037300119,0.008627156,0.00014777167,0.0004104837,0.000535205,0.015264998,0.00018933315,0.00133067,0.14348601],"study_design_scores_gemma":[0.34275138,0.50753754,0.12535755,0.0008989044,0.009421765,0.00030951336,0.00022097382,0.00076146924,0.006754052,0.0005652518,0.0053759664,0.000045580393],"about_ca_topic_score_codex":0.0012848423,"about_ca_topic_score_gemma":0.0028159556,"teacher_disagreement_score":0.002465342,"about_ca_system_score_codex":0.00025979677,"about_ca_system_score_gemma":0.0005087628,"threshold_uncertainty_score":0.013038099},"labels":[],"label_agreement":null},{"id":"W2068181643","doi":"10.1310/hct0805-311","title":"An Estimate of the Proportion of Symptoms Reported in Self-Administered Questionnaires That Are Captured as Adverse Drug Events in an Observational Database","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Pharmacovigilance and Adverse Drug Reactions","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; University Health Network","funders":"Ontario HIV Treatment Network","keywords":"Medicine; Interquartile range; Diarrhea; Nausea; Adverse effect; Cohort; Observational study; Cohort study; Pediatrics; Internal medicine","score_opus":0.5661113770237269,"score_gpt":0.6173921826787941,"score_spread":0.05128080565506721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068181643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9494499,0.0026069116,0.018055366,0.0004957124,0.00008951508,0.0005865609,0.025882067,0.00009482444,0.0027391156],"genre_scores_gemma":[0.98165095,0.0006185413,0.0045432583,0.00032339516,0.00009760627,0.0005394694,0.01189385,0.000016153928,0.00031672785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96946824,0.01616062,0.0047435914,0.0035857873,0.005327022,0.00071475876],"domain_scores_gemma":[0.90238994,0.042032916,0.036892403,0.0075962325,0.010189588,0.00089898525],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02488728,0.00049252703,0.0007700682,0.0037715328,0.00046853456,0.0014874176,0.0011708696,0.0009274769,0.00094742],"category_scores_gemma":[0.08048438,0.00049900915,0.0012809163,0.0039469176,0.00039126683,0.001537338,0.00116045,0.0006853143,0.00040501222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073085146,0.000016916156,0.9968982,0.00007551926,0.0003354557,0.000014403621,0.000065529784,0.00010476135,0.00008539021,0.000042226013,0.00024332832,0.0020452016],"study_design_scores_gemma":[0.000016690801,0.00009372067,0.99610955,0.000064735854,0.00017598638,0.0002788366,0.00013995137,0.001951386,0.00014913184,0.00005143846,0.0009573681,0.000011120582],"about_ca_topic_score_codex":0.01460376,"about_ca_topic_score_gemma":0.00844197,"teacher_disagreement_score":0.97511274,"about_ca_system_score_codex":0.0013216202,"about_ca_system_score_gemma":0.0009234692,"threshold_uncertainty_score":0.13161808},"labels":[],"label_agreement":null},{"id":"W2068355743","doi":"10.1310/hct0905-314","title":"A Prospective Study of Body Fat Redistribution, Lipid, and Glucose Parameters in HIV-Infected Patients Initiating Combination Antiretroviral Therapy","year":2008,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; McMaster University Medical Centre; University Health Network; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Lipodystrophy; Medicine; Prospective cohort study; Internal medicine; Triglyceride; Endocrinology; Antiretroviral therapy; Waist; Lipoatrophy; Diabetes mellitus; Anthropometry; Lipid profile; Stavudine; Metabolic syndrome; Insulin; Human immunodeficiency virus (HIV); Gastroenterology; Cholesterol; Body mass index; Viral load; Immunology","score_opus":0.1445983891358264,"score_gpt":0.4386299770869479,"score_spread":0.2940315879511215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068355743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99926966,0.00013322875,0.00005816748,0.000019680498,0.0000053138942,0.000017661147,0.00028313862,0.0000025034026,0.00021057576],"genre_scores_gemma":[0.99922967,0.00007968003,0.000105329214,0.000037859216,0.00001057044,0.000020748881,0.00036876736,0.000001777133,0.00014552574],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956113,0.00011952629,0.000044743647,0.00009478899,0.00009444088,0.0000852798],"domain_scores_gemma":[0.99883205,0.00018091993,0.00042973275,0.0001067728,0.00013063077,0.00031994394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005559869,0.00042024578,0.00048383637,0.0005956341,0.00087688444,0.0007790851,0.0002851398,0.00062083575,0.0014260957],"category_scores_gemma":[0.001659214,0.0005878116,0.00035720418,0.00092336704,0.00024808577,0.00055656186,0.0003154411,0.001021223,0.0003722796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001211639,0.000061271436,0.999073,0.0000035367616,0.00002225197,0.00007256711,0.000039799725,0.000011172946,0.00014764382,0.0000033292201,0.00002955547,0.00041463942],"study_design_scores_gemma":[0.000022918586,0.00042434543,0.9984982,0.0000058284127,0.00002537754,0.00058004353,0.00013334978,0.000095003415,0.000049960836,0.000007208573,0.0001537793,0.000004024457],"about_ca_topic_score_codex":0.0030751885,"about_ca_topic_score_gemma":0.0033555243,"teacher_disagreement_score":0.0030751885,"about_ca_system_score_codex":0.00022334226,"about_ca_system_score_gemma":0.00039419456,"threshold_uncertainty_score":0.0061145425},"labels":[],"label_agreement":null},{"id":"W2069363561","doi":"10.1310/b05e-tfvn-uj8l-mfhj","title":"Attenuated T-Lymphocyte Response to HIV Therapy in Individuals Receiving HMG-CoA Reductase Inhibitors","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Fibrate; Ritonavir; Nelfinavir; HMG-CoA reductase; Statin; Rosuvastatin; Atorvastatin; Internal medicine; Saquinavir; Pharmacology; Indinavir; Protease inhibitor (pharmacology); Integrase inhibitor; Viral load; Immunology; Reductase; Antiretroviral therapy; Human immunodeficiency virus (HIV)","score_opus":0.1986185197320598,"score_gpt":0.4835371366619322,"score_spread":0.2849186169298724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069363561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995633,0.00014622664,0.000031434476,0.000012729148,0.0000047462354,0.00000725332,0.00004797214,0.0000018373805,0.00018453812],"genre_scores_gemma":[0.99967027,0.00005148565,0.00003761257,0.000025503097,0.000010791114,0.00000619837,0.00008503149,7.7779055e-7,0.000112275826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996785,0.00008705399,0.000029746918,0.00006501266,0.000053115706,0.00008651478],"domain_scores_gemma":[0.99924964,0.00013441846,0.0003011834,0.000048935097,0.00008331105,0.00018258797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039959708,0.00033265818,0.0004119425,0.0005271942,0.00051572314,0.00052628765,0.00018858085,0.00042675206,0.0012204662],"category_scores_gemma":[0.0014460352,0.00024364228,0.0003331047,0.00035621444,0.00023870621,0.00028130924,0.00022825821,0.00051349396,0.00025959843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001574393,0.00017041845,0.9924982,0.000015758116,0.00005424941,0.0005078804,0.0001034145,0.00006392527,0.0021519584,0.000014983379,0.00004902821,0.0027958208],"study_design_scores_gemma":[0.00006701152,0.0022205128,0.9944074,0.000012686915,0.00008929217,0.0017937198,0.00015843491,0.00027582885,0.0005748816,0.000027526765,0.0003660106,0.0000066070284],"about_ca_topic_score_codex":0.0010662031,"about_ca_topic_score_gemma":0.00083011546,"teacher_disagreement_score":0.0012204662,"about_ca_system_score_codex":0.00020113778,"about_ca_system_score_gemma":0.00019128462,"threshold_uncertainty_score":0.0040828586},"labels":[],"label_agreement":null},{"id":"W2071621051","doi":"10.1310/hag3-8ya5-udqc-36nx","title":"Virologic and Immunologic Response to a Boosted Double-Protease Inhibitor-Based Therapy in Highly Pretreated HIV-1-Infected Patients","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Royal Victoria Regional Health Centre; McGill University Health Centre","funders":"Canadian Institutes of Health Research; Abbott Canada; Abbott Laboratories","keywords":"Saquinavir; Medicine; Lopinavir; Regimen; Protease inhibitor (pharmacology); Internal medicine; Ritonavir; Viral load; Lamivudine; Gastroenterology; Immunology; Odds ratio; Reverse-transcriptase inhibitor; Nelfinavir; Drug resistance; Pharmacology; Virology; Virus; Antiretroviral therapy; Biology","score_opus":0.12595465333192757,"score_gpt":0.40690000416868316,"score_spread":0.2809453508367556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071621051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995541,0.00023864351,0.00004673899,0.00001782913,0.0000030320664,0.00001110122,0.000018498882,0.000002656605,0.00010752926],"genre_scores_gemma":[0.99958485,0.000059216654,0.00015717397,0.000048238988,0.000015079746,0.0000093502795,0.00006714677,7.502152e-7,0.000057981208],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99977285,0.00011045724,0.000022856046,0.000033661123,0.000029749981,0.000030362044],"domain_scores_gemma":[0.9992679,0.00021998811,0.00024104698,0.000033831413,0.000033053257,0.00020415195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045480882,0.00024614178,0.00036609278,0.00009900496,0.00017256383,0.00025646205,0.00011624057,0.00028033656,0.0008579175],"category_scores_gemma":[0.0011986352,0.00014109524,0.00020334551,0.000085521984,0.00021396097,0.0001641363,0.00013272339,0.00041546486,0.00010616026],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02974271,0.0020169625,0.8784977,0.00020813051,0.00030320755,0.0008879478,0.0002511908,0.0010099225,0.037518423,0.00006491165,0.00043999424,0.04905885],"study_design_scores_gemma":[0.0019233227,0.044476654,0.943252,0.000032171894,0.00014346569,0.0026792956,0.00011449739,0.0015695106,0.0050019827,0.000046484456,0.00074184156,0.000018849247],"about_ca_topic_score_codex":0.00019844515,"about_ca_topic_score_gemma":0.00034877664,"teacher_disagreement_score":0.0008579175,"about_ca_system_score_codex":0.00016919895,"about_ca_system_score_gemma":0.0001846611,"threshold_uncertainty_score":0.0028700233},"labels":[],"label_agreement":null},{"id":"W2078593189","doi":"10.1310/2xvk-pbgl-735n-wh72","title":"Concomitant Use of an Active Boosted Protease Inhibitor with Enfuvirtide in Treatment-Experienced, HIV-Infected Individuals: Recent Data and Consensus Recommendations","year":2006,"lang":"en","type":"review","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal General Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Enfuvirtide; Ritonavir; Concomitant; Medicine; Protease inhibitor (pharmacology); Lopinavir; Regimen; Viral load; Pharmacology; Internal medicine; Protease; Virology; Human immunodeficiency virus (HIV); Immunology; Gp41; Antiretroviral therapy; Biology; Enzyme","score_opus":0.47053954744420085,"score_gpt":0.5174414029777028,"score_spread":0.04690185553350196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078593189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004419148,0.72657764,0.012250916,0.22661975,0.013336756,0.001740347,0.0012289736,0.00041013263,0.013416343],"genre_scores_gemma":[0.035740454,0.72499365,0.10098292,0.11074354,0.012296817,0.0040542963,0.004403945,0.00019362128,0.0065907054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97782636,0.0072340304,0.0075687487,0.0012626502,0.0052829264,0.000825349],"domain_scores_gemma":[0.9306256,0.024254728,0.010723269,0.0013911385,0.02939943,0.0036058344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035117835,0.0014139648,0.004544319,0.0027130174,0.0016627295,0.0037949872,0.007160585,0.008396632,0.0030043428],"category_scores_gemma":[0.038549665,0.0012407008,0.0055086026,0.0028688647,0.0018601852,0.0032051376,0.002344244,0.00925835,0.0022244842],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011654302,0.00067482714,0.0056535276,0.045815874,0.0022530167,0.0005411434,0.0006325732,0.0011969196,0.0013532693,0.0032714289,0.18916021,0.74828184],"study_design_scores_gemma":[0.0028724112,0.0012317576,0.019959636,0.13206302,0.007495023,0.0015239957,0.0016768406,0.0020248808,0.0018697706,0.010054517,0.81894726,0.00028081535],"about_ca_topic_score_codex":0.006483378,"about_ca_topic_score_gemma":0.013164749,"teacher_disagreement_score":0.035117835,"about_ca_system_score_codex":0.0023608778,"about_ca_system_score_gemma":0.009467993,"threshold_uncertainty_score":0.18572307},"labels":[],"label_agreement":null},{"id":"W2085481779","doi":"10.1310/hct1105-260","title":"A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Saskatchewan","keywords":"Raltegravir; Abacavir; Medicine; Lamivudine; Adverse effect; Viral load; Internal medicine; Discontinuation; Gastroenterology; Human immunodeficiency virus (HIV); Virology; Chronic hepatitis; Antiretroviral therapy","score_opus":0.15240359952108895,"score_gpt":0.4151683571378847,"score_spread":0.26276475761679574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085481779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973501,0.0008515724,0.00016327572,0.00021365797,0.000055780412,0.00035348957,0.00035306052,0.000042225132,0.0006168308],"genre_scores_gemma":[0.9958704,0.0005273632,0.00076337345,0.00035192788,0.00021370711,0.00045942835,0.000894565,0.000016765352,0.00090248446],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9990056,0.0006769256,0.00005140017,0.000078191944,0.000059632803,0.00012822113],"domain_scores_gemma":[0.99779534,0.00058681244,0.0003753918,0.00022139543,0.00013991121,0.0008811938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028061513,0.0012627653,0.0019847278,0.00022373059,0.0002693836,0.00068174815,0.0006314312,0.0008410513,0.003658925],"category_scores_gemma":[0.00184219,0.0005161611,0.0019173375,0.0001936091,0.00085201405,0.00080573116,0.00039843522,0.0020642194,0.0007178844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93736285,0.016452514,0.0072316024,0.00026175185,0.0013779318,0.00020119226,0.00021156252,0.00072515674,0.009383985,0.000112902446,0.0014250962,0.025253521],"study_design_scores_gemma":[0.5367233,0.44442528,0.014393548,0.000028271972,0.00063394255,0.0002963133,0.000071088274,0.0007540789,0.001329568,0.00010835419,0.0012063887,0.000029875482],"about_ca_topic_score_codex":0.00062580424,"about_ca_topic_score_gemma":0.0010445107,"teacher_disagreement_score":0.003658925,"about_ca_system_score_codex":0.00037960015,"about_ca_system_score_gemma":0.0009486253,"threshold_uncertainty_score":0.014840543},"labels":[],"label_agreement":null},{"id":"W2085670377","doi":"10.1310/hct1504-161","title":"Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial","year":2014,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McMaster University Medical Centre; University Health Network; Ottawa Hospital; Vancouver Infectious Diseases Centre; Université de Montréal; AIDS Vancouver; Concordia University; McGill University Health Centre; McGill University; HIV Legal Network; University of Toronto; Royal Victoria Hospital","funders":"","keywords":"Medicine; Ribavirin; Citalopram; Internal medicine; Placebo; Randomized controlled trial; Hepatitis C; Depression (economics); Pegylated interferon; Hepatitis C virus; Immunology; Antidepressant","score_opus":0.28603039124867446,"score_gpt":0.5005123531631583,"score_spread":0.21448196191448388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085670377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97149163,0.017308151,0.0005128871,0.0010081048,0.0008560869,0.0064271246,0.00077370444,0.000113986425,0.0015082945],"genre_scores_gemma":[0.9793707,0.010558431,0.0017154844,0.00090915995,0.0008122438,0.00421012,0.0004774794,0.00001627256,0.001930137],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993635,0.00031827073,0.00006285696,0.000099174504,0.000069251146,0.00008693788],"domain_scores_gemma":[0.99913424,0.00024695572,0.0002256351,0.00005437064,0.00009726385,0.0002415898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017093176,0.0011706693,0.0031150277,0.0004504942,0.0006202562,0.0010080549,0.0008694184,0.001969922,0.0044520977],"category_scores_gemma":[0.002061255,0.00068752805,0.0017236631,0.0006006904,0.00096422003,0.0005900301,0.0002864294,0.0018031921,0.0004221216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9792741,0.003575796,0.00040080523,0.0011907635,0.0009239066,0.00003278624,0.000040768984,0.00008673007,0.00200564,0.000048056114,0.00033387681,0.012086736],"study_design_scores_gemma":[0.97395045,0.023665197,0.0012537808,0.000047020145,0.00053774944,0.000016156519,0.000011002531,0.00012475964,0.00017145423,0.000022917035,0.00019219148,0.000007222383],"about_ca_topic_score_codex":0.0049341563,"about_ca_topic_score_gemma":0.009105541,"teacher_disagreement_score":0.0049341563,"about_ca_system_score_codex":0.00096047967,"about_ca_system_score_gemma":0.0018536646,"threshold_uncertainty_score":0.01489377},"labels":[],"label_agreement":null},{"id":"W2089422405","doi":"10.1310/0xh7-f2v2-1k0r-nu2w","title":"Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease","year":2005,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital; St. Paul's Hospital","funders":"","keywords":"Medicine; Enfuvirtide; Regimen; Internal medicine; Confidence interval; Odds ratio; Viral load; Randomization; Logistic regression; Clinical trial; Human immunodeficiency virus (HIV); Immunology","score_opus":0.08973515316492171,"score_gpt":0.4063030425292003,"score_spread":0.3165678893642786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089422405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987789,0.0004529945,0.00009062063,0.000090237896,0.000005147195,0.0000071465483,0.000087130225,0.000003990994,0.00048388928],"genre_scores_gemma":[0.99956053,0.000093486204,0.000091992086,0.000019335972,0.000016289636,0.000004488917,0.00015608467,9.1031046e-7,0.000056784018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998197,0.00006502965,0.000018468414,0.000028970479,0.000021259873,0.000046591267],"domain_scores_gemma":[0.9987803,0.0002999916,0.00053981494,0.000041746836,0.000050009327,0.0002881139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039382497,0.00032541383,0.00025943835,0.00032617632,0.00029569567,0.00048847764,0.0002094493,0.00041050542,0.0017696789],"category_scores_gemma":[0.0023780242,0.00010894469,0.00018255468,0.00031919812,0.00033008002,0.0003218904,0.0003325856,0.00044954548,0.00025249517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038546193,0.000017559287,0.9959216,0.000007859734,0.000012291555,0.00009166838,0.000029797851,0.00010079042,0.00024423184,0.000019310353,0.0001236007,0.0030458749],"study_design_scores_gemma":[0.00003669859,0.00032425192,0.9964294,0.000028454291,0.000039017043,0.0012316443,0.00015644281,0.0011356026,0.00021593452,0.00010556355,0.00029072104,0.0000063533353],"about_ca_topic_score_codex":0.0007077462,"about_ca_topic_score_gemma":0.0013577369,"teacher_disagreement_score":0.0017696789,"about_ca_system_score_codex":0.0001680402,"about_ca_system_score_gemma":0.0002427431,"threshold_uncertainty_score":0.0059202313},"labels":[],"label_agreement":null},{"id":"W2094521579","doi":"10.1310/hct1206-313","title":"Effect of Baseline Characteristics on the Efficacy and Safety of Once-Daily Darunavir/ Ritonavir in HIV-1–Infected, Treatment-Naïve ARTEMIS Patients at Week 96","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"ACT Government","keywords":"Medicine; Darunavir; Ritonavir; Coinfection; Internal medicine; Incidence (geometry); Adverse effect; Lopinavir; Hepatitis C; Gastroenterology; Human immunodeficiency virus (HIV); Viral load; Immunology; Antiretroviral therapy","score_opus":0.13167708687691224,"score_gpt":0.3890928780651015,"score_spread":0.25741579118818925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094521579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992489,0.00030953318,0.000037392256,0.00003263722,0.000008644409,0.000012938041,0.00008353567,0.0000036088973,0.000262733],"genre_scores_gemma":[0.99958473,0.000052481806,0.000043347878,0.000032547556,0.000010914353,0.0000125000915,0.00011316423,0.0000018553222,0.00014852335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99941635,0.0002720685,0.00006415183,0.000087348795,0.00009374483,0.00006633375],"domain_scores_gemma":[0.9972868,0.0013007814,0.00071667193,0.00013780405,0.00014038227,0.000417629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012475691,0.00023754172,0.0006714695,0.00013618507,0.00014052057,0.00039144594,0.00014443343,0.00033212677,0.0016034922],"category_scores_gemma":[0.003230921,0.00012733994,0.00057362864,0.00017227595,0.00015278363,0.0003683276,0.00011211237,0.0006240306,0.000216374],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28223273,0.0065226583,0.58135575,0.00025329276,0.0024363482,0.00065105676,0.00037609026,0.0025046696,0.032809597,0.00010264772,0.0012287063,0.08952637],"study_design_scores_gemma":[0.0025805936,0.04612041,0.9433575,0.000026831916,0.0005119193,0.00045645,0.00009401044,0.0019121261,0.0041314117,0.000061918,0.0007146384,0.000032078427],"about_ca_topic_score_codex":0.00028503843,"about_ca_topic_score_gemma":0.00048958685,"teacher_disagreement_score":0.0016034922,"about_ca_system_score_codex":0.0002651848,"about_ca_system_score_gemma":0.00020640437,"threshold_uncertainty_score":0.0065978765},"labels":[],"label_agreement":null},{"id":"W2097226982","doi":"10.1310/hct1206-323","title":"Four-Year Follow-Up of Polyalkylimide Gel Use for the Treatment of HIV-Associated Lipoatrophy","year":2011,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Dermatological and COVID-19 studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadians Living with HIV; University of Toronto; University Health Network; St. Michael's Hospital; Maple Leaf Medical Clinic; Women's College Hospital","funders":"","keywords":"Medicine; Anxiety; Depression (economics); Randomized controlled trial; Quality of life (healthcare); Internal medicine; Lipoatrophy; Human immunodeficiency virus (HIV); Patient satisfaction; Physical therapy; Surgery; Viral load; Antiretroviral therapy; Psychiatry; Immunology","score_opus":0.5745653611812509,"score_gpt":0.45863819170432824,"score_spread":0.11592716947692266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097226982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99539113,0.0030024038,0.00013203725,0.0001073787,0.0000602437,0.0005230828,0.0002556418,0.000010949712,0.0005171341],"genre_scores_gemma":[0.9975883,0.000656293,0.00024530568,0.00014161531,0.00007005881,0.00054036,0.00031557525,0.000002018116,0.0004405979],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9981845,0.0010056683,0.00019132969,0.00018608317,0.00019289339,0.00023944397],"domain_scores_gemma":[0.99711144,0.0007690594,0.0012739176,0.0001783646,0.0002839666,0.00038326593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042723683,0.00053030474,0.0014285055,0.00041177822,0.0005790692,0.0006017356,0.00045719714,0.0012717636,0.002680119],"category_scores_gemma":[0.004980041,0.00033057822,0.0015647947,0.00034783327,0.00047903392,0.0008153186,0.00043451824,0.0014685938,0.00028235934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78849447,0.028639536,0.07853718,0.0015312806,0.0037913187,0.00022090158,0.00035302326,0.0005646032,0.004903524,0.000079573496,0.0008354272,0.09204924],"study_design_scores_gemma":[0.1372291,0.5920087,0.25902468,0.00023744375,0.005453443,0.00019293779,0.00023073843,0.0008524655,0.0028047343,0.00010181098,0.0018030602,0.00006084446],"about_ca_topic_score_codex":0.0010681286,"about_ca_topic_score_gemma":0.0013635755,"teacher_disagreement_score":0.0042723683,"about_ca_system_score_codex":0.0005492917,"about_ca_system_score_gemma":0.00076216104,"threshold_uncertainty_score":0.02259475},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2105543437","doi":"10.1179/1528433614z.0000000015","title":"Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054)","year":2015,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Regimen; Lamivudine; Adverse effect; Emtricitabine; Internal medicine; Viral load; Surgery; Gastroenterology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Virology; Chronic hepatitis","score_opus":0.3198417514449129,"score_gpt":0.47750882426556046,"score_spread":0.15766707282064757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105543437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966558,0.0016952358,0.0001259904,0.00023832262,0.000046313442,0.0001917242,0.00040884217,0.000026853288,0.00061082176],"genre_scores_gemma":[0.9953744,0.0011522205,0.00052733085,0.0004516164,0.00013437429,0.00015854738,0.0013092653,0.000012624494,0.00087974896],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991027,0.0005194987,0.000051579053,0.000095902404,0.0001112098,0.000119111064],"domain_scores_gemma":[0.9977956,0.0007740155,0.00054616283,0.00017916676,0.00014292212,0.0005621258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003389711,0.00061003363,0.0009613296,0.0002052649,0.00024221645,0.0006552931,0.0007403578,0.0007748307,0.0038256482],"category_scores_gemma":[0.0020555486,0.00024335185,0.0009681244,0.0002262613,0.0005827528,0.00056559365,0.00024177114,0.0018393762,0.00043029184],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7327416,0.034614354,0.025729515,0.0006461566,0.0022320005,0.00022799341,0.0002711825,0.0016153363,0.020431528,0.00015333958,0.003153281,0.17818381],"study_design_scores_gemma":[0.39291814,0.5333108,0.06469133,0.00012081672,0.0018433088,0.0003544853,0.000098990844,0.0013318356,0.0030542593,0.00012703973,0.0021052624,0.000043799377],"about_ca_topic_score_codex":0.0011139781,"about_ca_topic_score_gemma":0.0019852794,"teacher_disagreement_score":0.0038256482,"about_ca_system_score_codex":0.00041638932,"about_ca_system_score_gemma":0.0008085088,"threshold_uncertainty_score":0.017926753},"labels":[],"label_agreement":null},{"id":"W2111884657","doi":"10.1310/hct1306-335","title":"Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Abacavir; Darunavir; Emtricitabine; Lamivudine; Regimen; Ritonavir; Internal medicine; Gastroenterology; Viral load; Creatinine; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Hepatitis B virus; Virus","score_opus":0.17419158608269425,"score_gpt":0.4424751159049179,"score_spread":0.26828352982222364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111884657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9114989,0.057049654,0.006949391,0.0029400876,0.0004405503,0.0015487848,0.0007936529,0.00046210815,0.018316844],"genre_scores_gemma":[0.9755652,0.008741773,0.007955506,0.000847725,0.00042971002,0.00025145602,0.0005463093,0.000024697285,0.0056375368],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998323,0.000048540587,0.000011188166,0.000016875467,0.00006210325,0.000028985545],"domain_scores_gemma":[0.9999341,0.0000054727598,0.000020667434,0.000005676433,0.00001048541,0.000023666018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002728751,0.0002691474,0.00032089735,0.00025490214,0.00023757888,0.00027072168,0.00031190403,0.00020782641,0.0025454366],"category_scores_gemma":[0.00021313349,0.000081951046,0.00019317337,0.00015714754,0.00013650334,0.00009823589,0.00012602338,0.00048284832,0.0007754176],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004623309,0.0025907431,0.028429443,0.00049313833,0.00019849541,0.0023361682,0.00019858593,0.00053759955,0.07411403,0.0006252575,0.011357676,0.8744956],"study_design_scores_gemma":[0.02854712,0.06283733,0.556927,0.00077778817,0.00090486184,0.026148275,0.00023624358,0.006872396,0.041445028,0.0012427846,0.27395147,0.0001097117],"about_ca_topic_score_codex":0.0022211012,"about_ca_topic_score_gemma":0.006179678,"teacher_disagreement_score":0.0025454366,"about_ca_system_score_codex":0.00044019884,"about_ca_system_score_gemma":0.00060971535,"threshold_uncertainty_score":0.008515358},"labels":[],"label_agreement":null},{"id":"W2122378285","doi":"10.1310/hct0806-421","title":"Evaluation of Stool Frequency and Stool Form as Measures of HIV-Related Diarrhea","year":2007,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; University Health Network; Mount Sinai Hospital; Health Sciences Centre; Sinai Health System; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences","funders":"University of Toronto; Innovative Research Group Project of the National Natural Science Foundation of China; University Health Network","keywords":"Diarrhea; Medicine; Internal medicine; Human immunodeficiency virus (HIV); Gastroenterology; Prospective cohort study; Antiretroviral therapy; Correlation; Viral load; Immunology","score_opus":0.3488472668489003,"score_gpt":0.5262927517135569,"score_spread":0.17744548486465667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122378285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997733,0.0011013583,0.00053960975,0.000036209378,0.0000067039987,0.00004877116,0.00018212716,0.000007616684,0.00034468953],"genre_scores_gemma":[0.99841523,0.00024141664,0.000927958,0.000019671192,0.000008573627,0.000042663556,0.00020916453,0.0000014063495,0.00013387538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99821365,0.0012858071,0.00013342866,0.000108282526,0.00021050374,0.000048421167],"domain_scores_gemma":[0.9953556,0.0017826876,0.002088158,0.00019478952,0.0003263934,0.00025245454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026974368,0.0005527251,0.000493553,0.00072774006,0.00024129466,0.0004490748,0.00026943473,0.00027479505,0.0010352633],"category_scores_gemma":[0.0074254344,0.00013818068,0.00037758952,0.0007066827,0.0003590812,0.00051683874,0.0004036058,0.00035529686,0.00013381267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004739018,0.000102010395,0.9922271,0.00004189246,0.00010013049,0.0000145487065,0.00003170679,0.00011080265,0.00022577003,0.000010465996,0.000031739044,0.006629991],"study_design_scores_gemma":[0.000037509006,0.0027002108,0.99547845,0.000021604745,0.00007996017,0.00021522498,0.00007509837,0.0008687739,0.0003223234,0.0000399062,0.00015404394,0.0000069449165],"about_ca_topic_score_codex":0.0006318279,"about_ca_topic_score_gemma":0.00092706294,"teacher_disagreement_score":0.0026974368,"about_ca_system_score_codex":0.00018220671,"about_ca_system_score_gemma":0.00028513817,"threshold_uncertainty_score":0.014265597},"labels":[],"label_agreement":null},{"id":"W2136451994","doi":"10.1310/7lyw-gqff-wprq-k3qw","title":"Clinical Impact of Double Protease Inhibitor Boosting with Lopinavir/Ritonavir and Amprenavir as Part of Salvage Antiretroviral Therapy","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; Women's College Hospital; Health Sciences Centre; Canadians Living with HIV; Sunnybrook Health Science Centre; University of Waterloo; University Health Network; University of Toronto; Montreal General Hospital; McGill University","funders":"Abbott Laboratories","keywords":"Lopinavir; Medicine; Amprenavir; Ritonavir; Regimen; Salvage therapy; Internal medicine; Hazard ratio; Atazanavir; Lopinavir/ritonavir; Protease inhibitor (pharmacology); Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Confidence interval; Immunology; Protease; Chemotherapy; HIV-1 protease","score_opus":0.20446275338973807,"score_gpt":0.483843551421669,"score_spread":0.27938079803193094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136451994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99896395,0.0004889294,0.000046375873,0.000046712375,0.000012708977,0.00001730149,0.000057099685,0.000002932309,0.00036396467],"genre_scores_gemma":[0.99939597,0.00014790805,0.000083889754,0.000066187,0.00002093681,0.000008577917,0.00014786531,0.0000011522154,0.0001274427],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993088,0.00019544178,0.000054506778,0.00014021488,0.0001794614,0.00012155943],"domain_scores_gemma":[0.9982595,0.00043570623,0.0006062703,0.00008937762,0.00009398934,0.00051514216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095441483,0.00022394846,0.00051337556,0.00011960747,0.00029922414,0.000638827,0.00023378718,0.00034735276,0.0014837501],"category_scores_gemma":[0.0027412886,0.00012717272,0.0006999219,0.00017127897,0.0001712716,0.00025011235,0.0002441818,0.00078974105,0.0001841087],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027263146,0.003647885,0.9008267,0.00011676754,0.0005094021,0.0008192155,0.00014540718,0.00038791887,0.004627092,0.000090488014,0.00059425214,0.060971785],"study_design_scores_gemma":[0.0014091681,0.029951535,0.96067894,0.00005943044,0.00055288995,0.0019032907,0.00019191681,0.0018348029,0.0018008116,0.00007061269,0.0015300753,0.000016508133],"about_ca_topic_score_codex":0.0015829863,"about_ca_topic_score_gemma":0.0019330296,"teacher_disagreement_score":0.0015829863,"about_ca_system_score_codex":0.00061887293,"about_ca_system_score_gemma":0.0008501318,"threshold_uncertainty_score":0.0050475},"labels":[],"label_agreement":null},{"id":"W2143379599","doi":"10.1310/fgmf-y0ly-dmx8-371v","title":"Predictors of Long-Term Immunological Outcome in Rebounding Patients on Protease Inhibitor-Based HAART After Initial Successful Virologic Suppression: Implications for Timing to Switch","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University; Bayer Corporation","keywords":"Medicine; Viremia; Viral load; Internal medicine; Protease inhibitor (pharmacology); Univariate analysis; Gastroenterology; Reverse-transcriptase inhibitor; Immunology; Retrospective cohort study; Multivariate analysis; Area under the curve; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.22046669565469398,"score_gpt":0.4709658042581454,"score_spread":0.25049910860345137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143379599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995547,0.000231445,0.00003777663,0.000032105527,0.0000034068978,0.0000028411723,0.00003878295,0.0000015355096,0.00009725746],"genre_scores_gemma":[0.99977285,0.000045450815,0.000032408254,0.000008754364,0.000010611992,0.00000236024,0.00008482856,7.976958e-7,0.000041983734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975556,0.00007776344,0.000030015923,0.000043230393,0.000036775436,0.000056607623],"domain_scores_gemma":[0.9975744,0.00072140404,0.0010065124,0.00007450666,0.00013999513,0.00048324608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006797098,0.000291504,0.00028294898,0.00037801897,0.00023194746,0.00048854237,0.0002620641,0.00048853864,0.0011643005],"category_scores_gemma":[0.0029820052,0.00013819885,0.00031484175,0.0003727244,0.000246613,0.00034216064,0.00021496501,0.0005813088,0.00023995072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002506197,0.000024802595,0.99865687,0.0000032118362,0.00001288117,0.00006347702,0.000013169532,0.000047630907,0.00013493332,0.0000034440297,0.00002269265,0.00076611777],"study_design_scores_gemma":[0.00001426989,0.00029087556,0.99858713,0.0000064152564,0.000021815107,0.00042625517,0.00006995862,0.00041153256,0.000078252866,0.00001237649,0.00007865997,0.0000025318093],"about_ca_topic_score_codex":0.0009236733,"about_ca_topic_score_gemma":0.0008037002,"teacher_disagreement_score":0.0011643005,"about_ca_system_score_codex":0.00017371052,"about_ca_system_score_gemma":0.00024494453,"threshold_uncertainty_score":0.0038949251},"labels":[],"label_agreement":null},{"id":"W2144136328","doi":"10.1310/hct1105-312","title":"A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen","year":2010,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; College of Medicine, University of Cincinnati; University at Buffalo; University of California, San Diego; BioCryst; Deutsches Krebsforschungszentrum; International AIDS Society; University of Cincinnati; Johns Hopkins University; ACT Government; Georgia Clinical and Translational Science Alliance; Tulane University; University of Minnesota; University of Rochester; University of Miami; Northwestern University; York University; Bristol-Myers Squibb; University of Pennsylvania; Gilead Sciences; Vanderbilt University; Emory University; University of Nebraska Medical Center; National Institutes of Health; Ohio State University; University of Southern California; GlaxoSmithKline","keywords":"Medicine; Abacavir; Zidovudine; Regimen; Internal medicine; Lamivudine; Clinical endpoint; Placebo; Viral load; Indinavir; Population; Efavirenz; Discontinuation; Adverse effect; Gastroenterology; Randomized controlled trial; Immunology; Human immunodeficiency virus (HIV); Antiretroviral therapy; Viral disease; Virus; Pathology","score_opus":0.06691439298854879,"score_gpt":0.3846769090118663,"score_spread":0.3177625160233175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144136328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800878,0.0043157227,0.00056659785,0.0008718938,0.0017716681,0.008651124,0.0008272219,0.00014497069,0.002762921],"genre_scores_gemma":[0.9833013,0.0021847384,0.001843782,0.0013294569,0.0010620635,0.0071262885,0.0007150077,0.000019023168,0.0024183772],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986517,0.0007838696,0.000096193,0.00022906234,0.00008645023,0.00015279125],"domain_scores_gemma":[0.9982439,0.0005811612,0.00037190836,0.00015900674,0.00013576022,0.0005082178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020765609,0.0018840168,0.0042605484,0.00058378966,0.0007275556,0.0014197059,0.0011840826,0.002688282,0.010222912],"category_scores_gemma":[0.00295745,0.0009489688,0.0018988043,0.00042697953,0.0016782144,0.0012231901,0.00054788153,0.003866172,0.0012606845],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99116,0.004087322,0.00013773337,0.00026619763,0.00032614966,0.000015080618,0.000021379252,0.00005870277,0.0005574388,0.000043232565,0.00017830075,0.0031484696],"study_design_scores_gemma":[0.9819748,0.017263053,0.00033530005,0.000014372341,0.00011419014,0.000007034631,0.0000063221205,0.00009277547,0.00005538672,0.00003477219,0.00009842792,0.0000036321644],"about_ca_topic_score_codex":0.001220454,"about_ca_topic_score_gemma":0.0021216837,"teacher_disagreement_score":0.010222912,"about_ca_system_score_codex":0.0007457724,"about_ca_system_score_gemma":0.0013635183,"threshold_uncertainty_score":0.03419906},"labels":[],"label_agreement":null},{"id":"W2152778462","doi":"10.1310/hct1004-207","title":"Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals","year":2009,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McMaster University","keywords":"Enfuvirtide; Medicine; Discontinuation; Human immunodeficiency virus (HIV); Virology; Antiretroviral therapy; Tenofovir; Internal medicine; Immunology; Viral load","score_opus":0.16061886623418828,"score_gpt":0.46734059060930044,"score_spread":0.30672172437511214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152778462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986589,0.00085185276,0.000055926528,0.000032579,0.000003605886,0.000014498374,0.00008124041,0.0000031221464,0.00029834008],"genre_scores_gemma":[0.9994062,0.00027949305,0.00005726242,0.0000384734,0.000017646755,0.000008909962,0.00013637223,0.0000010141136,0.000054669003],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955624,0.00018844786,0.00004383594,0.00006581407,0.00007668007,0.00006885025],"domain_scores_gemma":[0.99843246,0.0004772844,0.00082117796,0.00005883362,0.000048435984,0.00016177495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078040466,0.00026536436,0.00033980614,0.00033818957,0.0004197159,0.00044585823,0.00016510527,0.00036751843,0.0010751166],"category_scores_gemma":[0.0018531088,0.00014795396,0.0003751075,0.00042764022,0.00027556324,0.00018690834,0.00023012288,0.00030059056,0.000118365984],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016479517,0.00006692256,0.9862242,0.00004917855,0.00007748575,0.0005341484,0.00013362482,0.00012898089,0.0013519796,0.000016194552,0.00011832859,0.00965095],"study_design_scores_gemma":[0.000075978685,0.0014321245,0.9954188,0.000032078296,0.00008939816,0.0014626475,0.00012792926,0.00033855383,0.0004190741,0.00004307695,0.0005538524,0.0000066413563],"about_ca_topic_score_codex":0.0016432109,"about_ca_topic_score_gemma":0.0023208912,"teacher_disagreement_score":0.0016432109,"about_ca_system_score_codex":0.00031076808,"about_ca_system_score_gemma":0.0003678891,"threshold_uncertainty_score":0.0041272044},"labels":[],"label_agreement":null},{"id":"W2163692526","doi":"10.1310/vqxj-41x6-gja2-h6ag","title":"Effect of Protease Inhibitor-Based Highly Active Antiretroviral Therapy on Survival in HIV-Associated Advanced Kaposi's Sarcoma Patients Treated with Chemotherapy","year":2003,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Internal medicine; Vincristine; Regimen; Sarcoma; Gastroenterology; Indinavir; Chemotherapy regimen; Anthracycline; Protease inhibitor (pharmacology); Surgery; Viral load; Human immunodeficiency virus (HIV); Antiretroviral therapy; Immunology; Cyclophosphamide; Pathology; Cancer","score_opus":0.044704020480735865,"score_gpt":0.37712422728603234,"score_spread":0.3324202068052965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163692526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984402,0.0010183302,0.00003536391,0.000095849966,0.0000087405115,0.0000049386526,0.00006017124,0.0000017950131,0.00033458942],"genre_scores_gemma":[0.9996424,0.0001566467,0.000030997846,0.000038872295,0.00002017551,0.0000033684105,0.00006833754,4.969562e-7,0.00003868959],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954385,0.00020394793,0.000053273616,0.00004616378,0.00007162981,0.0000811734],"domain_scores_gemma":[0.9962115,0.001816333,0.0011377747,0.000088281326,0.00022247367,0.0005236092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005824482,0.00012531721,0.00035601328,0.00022604587,0.00027311558,0.00041486704,0.00012334222,0.00032048093,0.00088616874],"category_scores_gemma":[0.00522603,0.00008261493,0.00033024023,0.00037773422,0.00022480743,0.00034679903,0.00022191435,0.0004168983,0.000098252094],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024950244,0.00014253492,0.98023295,0.000033773682,0.0001613991,0.00031551448,0.00012673413,0.0003280672,0.0007215665,0.000025940684,0.00016849519,0.015248004],"study_design_scores_gemma":[0.00017150487,0.003259904,0.993079,0.000039396004,0.00018542542,0.0012341116,0.0001851448,0.00085981685,0.00031011098,0.00006203621,0.00060463225,0.000008837324],"about_ca_topic_score_codex":0.000520961,"about_ca_topic_score_gemma":0.0009834301,"teacher_disagreement_score":0.00088616874,"about_ca_system_score_codex":0.00019780512,"about_ca_system_score_gemma":0.0002099045,"threshold_uncertainty_score":0.0030803084},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"split"},{"id":"W2317708264","doi":"10.1310/hct1302-90","title":"Relationship of Chronic Hepatitis C Infection to Rates of AIDS-Defining Illnesses in a Canadian Cohort of HIV Seropositive Individuals Receiving Highly Active Antiretroviral Therapy","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Hepatitis C virus research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Ottawa; Simon Fraser University; McGill University; McGill University Health Centre; Ontario HIV Treatment Network; Women's College Hospital; Maple Leaf Medical Clinic; Public Health Ontario; Canadian AIDS Treatment Information Exchange; St. Paul's Hospital; University of British Columbia; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Multicenter AIDS Cohort Study; Cohort; Internal medicine; Hepatitis C virus; Immunology; Rate ratio; Poisson regression; Hepatitis C; Cohort study; Relative risk; Viral disease; Virology; Human immunodeficiency virus (HIV); Sida; Confidence interval; Virus; Population; Environmental health","score_opus":0.1866082505449775,"score_gpt":0.47778726822010853,"score_spread":0.291179017675131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317708264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99426275,0.0008832813,0.00010031,0.00030010103,0.00001451712,0.000032188724,0.0028223505,0.000014906124,0.0015695493],"genre_scores_gemma":[0.99822885,0.00038962642,0.00011890104,0.00004489909,0.0000064922374,0.000008634365,0.0008569668,0.0000036147978,0.0003419693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917585,0.000055161512,0.000043016567,0.00016058084,0.0003144251,0.00025092292],"domain_scores_gemma":[0.99754107,0.00015812942,0.00062096014,0.00012465278,0.0010034695,0.0005517917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008171359,0.000450929,0.00044345533,0.0014956504,0.0021182862,0.0012166012,0.0013846805,0.00062068546,0.0025546544],"category_scores_gemma":[0.0029896705,0.00050592655,0.00093966455,0.0022046817,0.00053348683,0.00034257778,0.0007182416,0.0010089086,0.00017866831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007327683,0.0000147931605,0.99805826,0.000011574082,0.000058896156,0.000042013056,0.00012216445,0.00006638571,0.00008597343,0.00003518386,0.00035862255,0.0010727342],"study_design_scores_gemma":[0.0000080216505,0.00002443053,0.9987797,0.000014045766,0.00004133063,0.000111522895,0.00022830132,0.00038737248,0.000025480938,0.00001708096,0.00035247882,0.000010287711],"about_ca_topic_score_codex":0.9815931,"about_ca_topic_score_gemma":0.9697128,"teacher_disagreement_score":0.018406928,"about_ca_system_score_codex":0.0106423935,"about_ca_system_score_gemma":0.015398265,"threshold_uncertainty_score":0.07721633},"labels":[],"label_agreement":null},{"id":"W2317972666","doi":"10.1080/15284336.2015.1111555","title":"Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles","year":2016,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Women's College Hospital; Maple Leaf Medical Clinic","funders":"","keywords":"Viremia; Medicine; Regimen; Virology; Drug resistance; Reverse-transcriptase inhibitor; Nucleoside Reverse Transcriptase Inhibitor; Resistance mutation; Viral load; Internal medicine; Immunology; Reverse transcriptase; Human immunodeficiency virus (HIV); Antiretroviral therapy; Biology; Polymerase chain reaction; Genetics","score_opus":0.10623582874814227,"score_gpt":0.3866071786211991,"score_spread":0.2803713498730568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2317972666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99888057,0.0002689236,0.0000866624,0.00003879669,0.0000038151647,0.000007101543,0.00029585802,0.000004150661,0.00041416677],"genre_scores_gemma":[0.9992557,0.000093936294,0.00008374331,0.000017561908,0.000009333821,0.000007859356,0.00037415823,0.000002314349,0.00015549755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996424,0.000050734532,0.000042934167,0.000095043644,0.00007630477,0.00009272605],"domain_scores_gemma":[0.99752206,0.0005155637,0.001343139,0.000075826836,0.00013595073,0.0004074318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045827864,0.00017811533,0.00023976139,0.00043121594,0.00038890867,0.0007460216,0.00024934163,0.00031911413,0.0041435277],"category_scores_gemma":[0.0026499473,0.00011002336,0.00042704158,0.0004961487,0.00018553543,0.00043057516,0.00033423366,0.0006185993,0.00037899558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018149598,0.000026564761,0.9971174,0.0000073549704,0.000017586388,0.000119589036,0.000041824052,0.00007243405,0.00012490155,0.000032731354,0.000059175014,0.0021988817],"study_design_scores_gemma":[0.000011456576,0.00031163968,0.99675983,0.000015372729,0.000025242776,0.0016853912,0.00012307095,0.00041659825,0.00019085156,0.00009831226,0.00035520244,0.000007048721],"about_ca_topic_score_codex":0.0013289073,"about_ca_topic_score_gemma":0.0010841597,"teacher_disagreement_score":0.0041435277,"about_ca_system_score_codex":0.00039522088,"about_ca_system_score_gemma":0.00041085033,"threshold_uncertainty_score":0.013861537},"labels":[],"label_agreement":null},{"id":"W2411587754","doi":"10.1080/15284336.2016.1184827","title":"Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials","year":2016,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic; University of Toronto; Public Health Ontario; University Health Network","funders":"Canadian Institutes of Health Research; Ontario HIV Treatment Network","keywords":"Medicine; Cart; Immune system; Inflammation; Systemic inflammation; Immunology; Tolerability; Probiotic; Population; Placebo; Gut flora; Internal medicine; Adverse effect; Biology; Pathology","score_opus":0.1655538968730954,"score_gpt":0.44157794288070523,"score_spread":0.2760240460076098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411587754","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9176172,0.014105179,0.003140828,0.0026468786,0.00217266,0.055160746,0.0014508235,0.000091825335,0.0036137972],"genre_scores_gemma":[0.90184706,0.0070135375,0.008406635,0.0036553598,0.0020883663,0.07236416,0.0009170729,0.000030201953,0.0036776091],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99293065,0.0054534203,0.00047539614,0.00039505013,0.00032014368,0.00042534675],"domain_scores_gemma":[0.9935901,0.0024339869,0.0017551935,0.00061912247,0.00056611624,0.0010353592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01269448,0.0022458448,0.0029998315,0.00053330587,0.00095538684,0.0014656954,0.0012999666,0.0042971615,0.005772871],"category_scores_gemma":[0.01142367,0.0010419983,0.0038009912,0.0006447979,0.0015321414,0.0018045933,0.0010244703,0.0027578517,0.0007731933],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9662171,0.015281425,0.0011347069,0.0011101756,0.0023355372,0.000024980496,0.00009652848,0.00020682195,0.0015125833,0.00020489721,0.00033533972,0.011539893],"study_design_scores_gemma":[0.62515223,0.36786795,0.0023639696,0.00018624442,0.0021721758,0.000016085856,0.000055663568,0.0001789893,0.0005675448,0.00034100504,0.0010775455,0.00002059375],"about_ca_topic_score_codex":0.0008919303,"about_ca_topic_score_gemma":0.0016609408,"teacher_disagreement_score":0.01269448,"about_ca_system_score_codex":0.0006177974,"about_ca_system_score_gemma":0.001879301,"threshold_uncertainty_score":0.06713563},"labels":[],"label_agreement":null},{"id":"W4239380123","doi":"10.1310/hct1301-023","title":"High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1&lt;sub&gt;2009&lt;/sub&gt; and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults","year":2012,"lang":"en","type":"article","venue":"HIV Clinical Trials","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Agency of Canada; University of British Columbia; Dalhousie University; University of Toronto; McGill University; Ottawa Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Immunogenicity; Seroconversion; Dosing; Booster dose; Booster (rocketry); Immunology; Live attenuated influenza vaccine; Influenza vaccine; Immunization; Internal medicine; Vaccination; Virology; Antigen; Human immunodeficiency virus (HIV)","score_opus":0.15416824133214285,"score_gpt":0.4268660800435144,"score_spread":0.27269783871137154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239380123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710447,0.0007778913,0.00020204335,0.0002288135,0.00013684608,0.00084594137,0.00013960808,0.000025872994,0.0005385768],"genre_scores_gemma":[0.99688464,0.00041157403,0.00063697645,0.00034573648,0.0001542898,0.0008036644,0.0001778468,0.0000069415673,0.00057825464],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991284,0.0005349052,0.00006601145,0.000105668754,0.00006172674,0.00010339522],"domain_scores_gemma":[0.9987627,0.0003116108,0.00034530056,0.00010746145,0.00007980908,0.00039320698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027141788,0.0008950074,0.0012800272,0.0002504254,0.00033649552,0.00080316275,0.00057625026,0.001134691,0.0040779696],"category_scores_gemma":[0.0015944245,0.00052795676,0.0011365126,0.00019533916,0.0009197807,0.0007759106,0.00034397325,0.0022560123,0.0004933724],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9680217,0.012734212,0.0020337543,0.0002937054,0.0008514394,0.000021801547,0.00006511471,0.00017810566,0.0037983593,0.00006728632,0.0004809337,0.011453574],"study_design_scores_gemma":[0.8027619,0.1882779,0.005873937,0.000039588132,0.00064737623,0.000034554352,0.000025383564,0.0004068965,0.0014362211,0.00008857039,0.00039664356,0.000010984528],"about_ca_topic_score_codex":0.00059747515,"about_ca_topic_score_gemma":0.0009892192,"teacher_disagreement_score":0.0040779696,"about_ca_system_score_codex":0.00054735487,"about_ca_system_score_gemma":0.00088999735,"threshold_uncertainty_score":0.01435411},"labels":[],"label_agreement":null}]}